AU2020454132A1 - Methods and compositions for treating chemotherapy-induced diarrhea - Google Patents
Methods and compositions for treating chemotherapy-induced diarrhea Download PDFInfo
- Publication number
- AU2020454132A1 AU2020454132A1 AU2020454132A AU2020454132A AU2020454132A1 AU 2020454132 A1 AU2020454132 A1 AU 2020454132A1 AU 2020454132 A AU2020454132 A AU 2020454132A AU 2020454132 A AU2020454132 A AU 2020454132A AU 2020454132 A1 AU2020454132 A1 AU 2020454132A1
- Authority
- AU
- Australia
- Prior art keywords
- crofelemer
- cancer
- chemotherapy
- diarrhea
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012735 Diarrhoea Diseases 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims abstract description 85
- 238000002512 chemotherapy Methods 0.000 title claims description 90
- 239000000203 mixture Substances 0.000 title claims description 77
- 229920001393 Crofelemer Polymers 0.000 claims abstract description 208
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical group C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 claims abstract description 208
- 229940047615 crofelemer Drugs 0.000 claims abstract description 207
- 238000011282 treatment Methods 0.000 claims abstract description 118
- 208000024891 symptom Diseases 0.000 claims abstract description 28
- 239000003112 inhibitor Substances 0.000 claims abstract description 23
- 208000002193 Pain Diseases 0.000 claims abstract description 4
- 230000033001 locomotion Effects 0.000 claims description 43
- 230000007423 decrease Effects 0.000 claims description 40
- 229950008835 neratinib Drugs 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 30
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 25
- 241000282414 Homo sapiens Species 0.000 claims description 24
- -1 afatninib Chemical compound 0.000 claims description 24
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims description 20
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 20
- 239000012829 chemotherapy agent Substances 0.000 claims description 19
- 239000006186 oral dosage form Substances 0.000 claims description 19
- 229960002087 pertuzumab Drugs 0.000 claims description 19
- 229960000575 trastuzumab Drugs 0.000 claims description 19
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 17
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 17
- 230000006872 improvement Effects 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 12
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 11
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 11
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 11
- 229960001433 erlotinib Drugs 0.000 claims description 10
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 9
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 9
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 9
- 229940127089 cytotoxic agent Drugs 0.000 claims description 9
- 229960003668 docetaxel Drugs 0.000 claims description 9
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 9
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 9
- 229960004891 lapatinib Drugs 0.000 claims description 9
- 229960001592 paclitaxel Drugs 0.000 claims description 9
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 8
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 8
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 7
- 229960003005 axitinib Drugs 0.000 claims description 7
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 claims description 7
- 229960002584 gefitinib Drugs 0.000 claims description 7
- 229960002411 imatinib Drugs 0.000 claims description 7
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 7
- 229940120982 tarceva Drugs 0.000 claims description 7
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 6
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 6
- 208000034347 Faecal incontinence Diseases 0.000 claims description 6
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 6
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 6
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 6
- 231100000026 common toxicity Toxicity 0.000 claims description 6
- 229960005061 crizotinib Drugs 0.000 claims description 6
- 229940022353 herceptin Drugs 0.000 claims description 6
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 5
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 5
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 5
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 5
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 5
- 229960003736 bosutinib Drugs 0.000 claims description 5
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 229960002448 dasatinib Drugs 0.000 claims description 5
- 229960000639 pazopanib Drugs 0.000 claims description 5
- 229910052697 platinum Inorganic materials 0.000 claims description 5
- 229960003787 sorafenib Drugs 0.000 claims description 5
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 4
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 4
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 4
- 230000003187 abdominal effect Effects 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229960000106 biosimilars Drugs 0.000 claims description 4
- 229960001292 cabozantinib Drugs 0.000 claims description 4
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 4
- 229960001346 nilotinib Drugs 0.000 claims description 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 229960000215 ruxolitinib Drugs 0.000 claims description 4
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 4
- 229960001796 sunitinib Drugs 0.000 claims description 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 108090000323 DNA Topoisomerases Proteins 0.000 claims description 3
- 102000003915 DNA Topoisomerases Human genes 0.000 claims description 3
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims description 3
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 230000001668 ameliorated effect Effects 0.000 claims description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 229960001602 ceritinib Drugs 0.000 claims description 3
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 3
- 229940127096 cytoskeletal disruptor Drugs 0.000 claims description 3
- 229950002205 dacomitinib Drugs 0.000 claims description 3
- 229930013356 epothilone Natural products 0.000 claims description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 3
- 229960003784 lenvatinib Drugs 0.000 claims description 3
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 3
- 239000002243 precursor Substances 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical group S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 claims description 2
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006143 Brain stem glioma Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 2
- 206010073069 Hepatic cancer Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 229950001573 abemaciclib Drugs 0.000 claims description 2
- 229950010482 alpelisib Drugs 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000010175 gallbladder cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 229950003463 tucatinib Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 2
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 2
- 229960001611 alectinib Drugs 0.000 claims 1
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract description 3
- 206010000059 abdominal discomfort Diseases 0.000 abstract description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 127
- 229920000642 polymer Polymers 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 31
- 239000003826 tablet Substances 0.000 description 30
- 239000003814 drug Substances 0.000 description 29
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 27
- 229920001991 Proanthocyanidin Polymers 0.000 description 27
- 239000003819 Toceranib Substances 0.000 description 27
- 230000002550 fecal effect Effects 0.000 description 23
- 229940079593 drug Drugs 0.000 description 21
- 210000003608 fece Anatomy 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 19
- 238000009472 formulation Methods 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 16
- AOORBROPMMRREB-HBPAQXCTSA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 AOORBROPMMRREB-HBPAQXCTSA-N 0.000 description 14
- 229960005432 toceranib phosphate Drugs 0.000 description 14
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 229940090244 palladia Drugs 0.000 description 12
- 241001648676 Croton lechleri Species 0.000 description 11
- 244000168525 Croton tiglium Species 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 239000002702 enteric coating Substances 0.000 description 11
- 238000009505 enteric coating Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000002411 adverse Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000003560 cancer drug Substances 0.000 description 8
- 229920002770 condensed tannin Polymers 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000002483 medication Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229960004679 doxorubicin Drugs 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241001246270 Calophyllum Species 0.000 description 6
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 6
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- 101000653548 Homo sapiens Trichoplein keratin filament-binding protein Proteins 0.000 description 6
- 102100030645 Trichoplein keratin filament-binding protein Human genes 0.000 description 6
- 230000001142 anti-diarrhea Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229940044683 chemotherapy drug Drugs 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 6
- 229960001571 loperamide Drugs 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 6
- YCCHNFGPIFYNTF-UHFFFAOYSA-N tertiary cymene hydroperoxide Natural products CC1=CC=C(C(C)(C)OO)C=C1 YCCHNFGPIFYNTF-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 6
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 5
- 108010081667 aflibercept Proteins 0.000 description 5
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 230000000741 diarrhetic effect Effects 0.000 description 5
- UFNVPOGXISZXJD-JBQZKEIOSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-JBQZKEIOSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
- GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 description 4
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960004117 capecitabine Drugs 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 229950009822 gimeracil Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960004768 irinotecan Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229960005415 pasireotide Drugs 0.000 description 4
- VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 description 4
- 108700017947 pasireotide Proteins 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- VCMMXZQDRFWYSE-UHFFFAOYSA-N plumbagin Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1O VCMMXZQDRFWYSE-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 208000026775 severe diarrhea Diseases 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 4
- 229960001674 tegafur Drugs 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 3
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 108010062745 Chloride Channels Proteins 0.000 description 3
- 102000011045 Chloride Channels Human genes 0.000 description 3
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 201000009840 acute diarrhea Diseases 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 239000003793 antidiarrheal agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 229960000997 bicalutamide Drugs 0.000 description 3
- 229960001573 cabazitaxel Drugs 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000009104 chemotherapy regimen Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002465 dabrafenib Drugs 0.000 description 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- 229960003649 eribulin Drugs 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960002258 fulvestrant Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229950000193 oteracil Drugs 0.000 description 3
- NEEFMPSSNFRRNC-HQUONIRXSA-N pasireotide aspartate Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CC(O)=O.C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 NEEFMPSSNFRRNC-HQUONIRXSA-N 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 3
- 229960005079 pemetrexed Drugs 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229960004836 regorafenib Drugs 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 3
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 3
- 108010091666 romidepsin Proteins 0.000 description 3
- 201000009881 secretory diarrhea Diseases 0.000 description 3
- 229940050423 signifor Drugs 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 229960003454 tamoxifen citrate Drugs 0.000 description 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 238000002562 urinalysis Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 229960003862 vemurafenib Drugs 0.000 description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 3
- 210000004916 vomit Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 229960002760 ziv-aflibercept Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 2
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 244000060234 Gmelina philippensis Species 0.000 description 2
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- ZMOIGGHUSNHCAB-UHFFFAOYSA-N Isoplumbagin Natural products C1=CC(O)=C2C(=O)C(C)=CC(=O)C2=C1 ZMOIGGHUSNHCAB-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 2
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 2
- 108010016076 Octreotide Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000038030 PI3Ks Human genes 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940110282 alimta Drugs 0.000 description 2
- 229940118662 aluminum carbonate Drugs 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001262 anti-secretory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125714 antidiarrheal agent Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229940078010 arimidex Drugs 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- ALPCEXCHMFUSAN-UHFFFAOYSA-N beta-Dihydroplumbagin Natural products C1=CC=C2C(=O)C(C)CC(=O)C2=C1O ALPCEXCHMFUSAN-UHFFFAOYSA-N 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 229940097647 casodex Drugs 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 230000004640 cellular pathway Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- 229920001688 coating polymer Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229940124301 concurrent medication Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229940047587 crofelemer 125 mg Drugs 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000013481 data capture Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940115080 doxil Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229940120655 eloxatin Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 229940014684 erivedge Drugs 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 229940087861 faslodex Drugs 0.000 description 2
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical compound OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940020967 gemzar Drugs 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 229940118951 halaven Drugs 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940005319 inlyta Drugs 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 2
- 229940025735 jevtana Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- MPVGZUGXCQEXTM-UHFFFAOYSA-N linifanib Chemical compound CC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)C=2C=3C(N)=NNC=3C=CC=2)=C1 MPVGZUGXCQEXTM-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 231100000647 material safety data sheet Toxicity 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- 229940085033 nolvadex Drugs 0.000 description 2
- 229960002700 octreotide Drugs 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229960004432 raltitrexed Drugs 0.000 description 2
- 238000013102 re-test Methods 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229940090374 stivarga Drugs 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 229940061353 temodar Drugs 0.000 description 2
- 229940100411 torisel Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229940094060 tykerb Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 2
- 229940069559 votrient Drugs 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 229940049068 xalkori Drugs 0.000 description 2
- 229940053867 xeloda Drugs 0.000 description 2
- 229940036061 zaltrap Drugs 0.000 description 2
- 229940033942 zoladex Drugs 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- WCWUXEGQKLTGDX-LLVKDONJSA-N (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@H](O)C)=C1 WCWUXEGQKLTGDX-LLVKDONJSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UUBHZHZSIKRVIV-KCXSXWJSSA-N (2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\C=C\C(\C)=C\C(O)=O UUBHZHZSIKRVIV-KCXSXWJSSA-N 0.000 description 1
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- VXZCUHNJXSIJIM-MEBGWEOYSA-N (z)-but-2-enedioic acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound OC(=O)\C=C/C(O)=O.C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 VXZCUHNJXSIJIM-MEBGWEOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WPHKIQPVPYJNAX-UHFFFAOYSA-N 1-[4-[4-amino-7-[1-(2-hydroxyethyl)pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl]phenyl]-3-(3-fluorophenyl)urea Chemical compound C1=2SC=C(C=3C=CC(NC(=O)NC=4C=C(F)C=CC=4)=CC=3)C=2C(N)=NC=C1C=1C=NN(CCO)C=1 WPHKIQPVPYJNAX-UHFFFAOYSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
- 241000349750 Baphia nitida Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 240000007857 Castanea sativa Species 0.000 description 1
- 235000014037 Castanea sativa Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000741487 Croton draconoides Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- HEAUOKZIVMZVQL-VWLOTQADSA-N Elagolix Chemical compound COC1=CC=CC(C=2C(N(C[C@H](NCCCC(O)=O)C=3C=CC=CC=3)C(=O)N(CC=3C(=CC=CC=3F)C(F)(F)F)C=2C)=O)=C1F HEAUOKZIVMZVQL-VWLOTQADSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241001481760 Erethizon dorsatum Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 108700031843 GRB7 Adaptor Proteins 0.000 description 1
- 101150052409 GRB7 gene Proteins 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000032320 Germ cell tumor of testis Diseases 0.000 description 1
- 208000009139 Gilbert Disease Diseases 0.000 description 1
- 208000022412 Gilbert syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010056559 Graft infection Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102000014736 Notch Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000308676 Pterocarpus officinalis Species 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 208000035999 Recurrence Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 101710184310 Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical class CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- JIFPTBLGXRKRAO-UHFFFAOYSA-K aluminum;magnesium;hydroxide;sulfate Chemical compound [OH-].[Mg+2].[Al+3].[O-]S([O-])(=O)=O JIFPTBLGXRKRAO-UHFFFAOYSA-K 0.000 description 1
- SEIGJEJVIMIXIU-UHFFFAOYSA-J aluminum;sodium;carbonate;dihydroxide Chemical compound [Na+].O[Al+]O.[O-]C([O-])=O SEIGJEJVIMIXIU-UHFFFAOYSA-J 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229960001482 bismuth subnitrate Drugs 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 229940088954 camptosar Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- PGMBSCDPACPRSG-SCSDYSBLSA-N capiri Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 PGMBSCDPACPRSG-SCSDYSBLSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940015828 dihydroxyaluminum sodium carbonate Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 239000009136 dragon's blood Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 229950004823 elagolix Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000005835 flavan-3,4-diols Chemical class 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229950000568 ilorasertib Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229950002133 iniparib Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940011083 istodax Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- 229940111707 ixempra Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229950002216 linifanib Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229960004018 magaldrate Drugs 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000025402 neoplasm of esophagus Diseases 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229950003600 ombrabulin Drugs 0.000 description 1
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229950006354 orantinib Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229950010307 peretinoin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 229960002633 ramucirumab Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940127558 rescue medication Drugs 0.000 description 1
- FECGNJPYVFEKOD-VMPITWQZSA-N resminostat Chemical compound C1=CC(CN(C)C)=CC=C1S(=O)(=O)N1C=C(\C=C\C(=O)NO)C=C1 FECGNJPYVFEKOD-VMPITWQZSA-N 0.000 description 1
- 229950002821 resminostat Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940068117 sprycel Drugs 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002812 sunitinib malate Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229950001899 tasquinimod Drugs 0.000 description 1
- ONDYALNGTUAJDX-UHFFFAOYSA-N tasquinimod Chemical compound OC=1C=2C(OC)=CC=CC=2N(C)C(=O)C=1C(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 ONDYALNGTUAJDX-UHFFFAOYSA-N 0.000 description 1
- 208000002918 testicular germ cell tumor Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 229960005048 toceranib Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 108010075758 trebananib Proteins 0.000 description 1
- 229950001210 trebananib Drugs 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Description
METHODS AND COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED DIARRHEA
FIELD OF THE INVENTION
[0001] The present invention is directed to methods of preventing, ameliorating and/or treating diarrhea. More specifically, the methods presented herein prevent, ameliorate or treat chemotherapy-induced diarrhea (CID) using a proanthocyanidin such as crofelemer in combination with a chemotherapy agent.
BACKGROUND
[0002] Diarrhea is a common occurrence in human cancer patients that can result from radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease and infections or a combination thereof. In particular, chemotherapy-induced diarrhea (CID) is common, especially in patients with advanced cancer, and has to be assessed for etiologies associated with the chemotherapeutic regimen or not [Gibson, R. and Stringer, A., Curr Opin Support Palliat Care 3: 31-35, 2009] Careful analysis can result in better management of the diarrheal symptoms to prevent severe complications that may be irreversible [Davila, M. and Bresalier, R., Nat Clin Pract Gastroenterol Hepatol 5: 682-696, 2008; Vincenzi, B. et al. Nat Clin Pract Oncol 5: 455-465, 2008] Sequelae can include dehydration, malnutrition, cardiovascular issues, and even death.
[0003] CID is very prevalent depending on the chemotherapy regime with an estimated prevalence of between about 50-80% in patients [Benson, A. et al. J Clin Oncol 22: 2918— 2926, 2004; Gibson, R. and Stringer, A., Curr Opin Support Palliat Care 3: 31-35, 2009] especially those treated with 5-fluorouracil bolus or some combination therapies of irinotecan and fluoropyrimi dines (IFL, XELIRI). Regardless of the molecular targeted approach of tyrosine kinase inhibitors and antibodies, diarrhea is a common side effect in up to 60% of patients with up to 10% having severe diarrhea. Furthermore, the underlying pathophysiology is still under investigation.
[0004] Therapeutic agents commonly causing diarrhea include 5-fluorouracil (5-FU), capecitabine and irinotecan (CPT-11) [Benson, A. et al. J Clin Oncol 22: 2918-2926, 2004;
Keefe, D. et al. Semin Oncol Nurs 20: 38-47, 2004] It is often a dose-related adverse effect and may be associated with other features of toxicity. CID appears to be a multifactorial process whereby acute damage to the intestinal mucosa (including loss of intestinal epithelium, superficial necrosis and inflammation of the bowel wall) causes an imbalance between absorption and secretion in the small bowel [Keefe, D. etal. Gut 47: 632-637, 2000; Keefe, D. Support Care Cancer 15: 483-490, 2007; Gibson, R. and Stringer, A., Curr Opin Support Palliat Care 3: 31-35, 2009]
[0005] Left untreated, life-threatening gastrointestinal syndrome is recognized by two National Cancer Institute-sponsored cooperative group trials as a serious complication. These trials reviewed early toxic deaths occurring in irinotecan plus high-dose fluorouracil and leucovorin for advanced colorectal cancer and highlighted the need for vigilant monitoring and aggressive therapy for this serious complication [Conti, J. et al. J Clin Oncol 14: 709-715, 1996; Arbuckle, R. et al. Oncologist 5: 250-259, 2000; Saltz L. et al. N Engl J Med 343: 905- 914, 2000] In addition, diarrhea can hinder chemotherapy and other treatments for cancer by causing dosing delays, reductions, or use of alternative agents which may have an ultimate impact on survival [Engelking, C. et al., Oncol Nurs Forum 25: 859-860 1998; Ippoliti, A., Am J Health Syst Pharm 55: 1573-1580, 1998]
[0006] Therefore, drug-related diarrhea in human subjects undergoing chemotherapy represents an important and unmet clinical need requiring more effective management. Currently prescribed therapies are only partially effective or are plagued by unacceptable side effects such as constipation and the potential for addiction. The development of a drug for the treatment of chemotherapy-associated diarrhea with a low potential for drug-drug interactions, effects on drug metabolism, or abuse potential would provide an important benefit for subjects undergoing chemotherapy.
SUMMARY
[0007] Disclosed herein are methods of preventing, ameliorating and/or treating diarrhea in human subjects being administered or having been administered a chemotherapy regimen. In one embodiment, the methods presented herein prevent, ameliorate or treat chemotherapy- induced diarrhea (CID).
[0008] In one aspect, provided herein are methods of treating CID in a human subject undergoing chemotherapy, particularly for cancer treatment, comprising administering to a subject in need thereof a composition comprising an effective amount of a proanthocyanidin polymer composition from C. lechleri, preferably crofelemer, to treat, ameliorate or prevent CID. In certain embodiments, the crofelemer is an enterically protected formulation. In certain embodiments the chemotherapy is administered to treat, ameliorate, manage or prevent cancer.
[0009] According to certain embodiments, crofelemer may be administered in combination with other chemotherapy agents.
[0010] In one embodiment, the crofelemer is administered at the same time as administration of chemotherapy to reduce or delay the onset of CID.
[0011] In certain embodiments, the subject exhibits Grade 1, Grade 2, Grade 3 or Grade 4 diarrhea in accordance with the Common Toxicity Criteria from the National Cancer Institute.
[0012] In one embodiment, the crofelemer is administered before administration of chemotherapy to reduce or delay the onset of CID.
[0013] In one embodiment, the crofelemer is administered after administration of chemotherapy to reduce the onset of or treat CID.
[0014] In certain embodiments, the crofelemer is administered to reduce the risk, incidence or severity of CID so that the human subject can tolerate a particular chemotherapy agent with CID as a side effect or a higher dose of a chemotherapy agent that has CID as a side effect.
[0015] In one embodiment, the chemotherapy agent is selected from alkylating agents, anthracyclines, cytoskeletal disruptors (taxanes), epothilones, histone deacetylase inhibitors, inhibitors of topoisomerase I, inhibitors of topoisomerase II, kinase inhibitors, nucleotide analogs and precursor analogs, peptide antibiotics, platinum-based agents and retinoids.
[0016] In one embodiment, the chemotherapy agent comprises one or more tyrosine kinase inhibitors. The tyrosine kinase inhibitor (TKI) have a target selected from epithelial growth factor receptor (EGFR), VEGFR (e g, VEGFR-1, VEGFR-2, and/or VEGFR-3); AXL, RET, TYR03, MER, KIT, TRKB, FLT-3, CSF-1R, anaplastic lymphoma kinase (ALK), ROS-1 (c- ros); hepatocyte growth factor receptor (HGFR), c-Met, RON, platelet derived growth factor
receptor (PDGFR) a and b, fibroblast growth factor receptor (FGFR1,2,3, or 4), KIT, Lck, Fms, Itk, BRAF, mutant BRAF, c-CRAF, BRK, EPHRs, and TIE-2, In one embodiment, the chemotherapy agent comprises one or more EGFR TKIs. In one embodiment, the chemotherapy agent comprises one or more a pan-ErbB receptor TKIs. In one embodiment, the chemotherapy agent comprises EGFR TKI and a pan-ErbB receptor TKI.
[0017] In one embodiment, the tyrosine kinase inhibitor is selected from lapatinib, sunitinib, sorafenib, erlotinib, gefitinib, axitinib, imatinib, nilotinib, dasatinib, cabozantinib, ruxolitinib, neratinib, bosutinib, pazopanib, afatninib, lenvatinib, tucatinib, vandetanib, ceritinib, crizotinib, dacomitinib, and valatinib.
[0018] In one embodiment, the chemotherapy is a phosphoinositide 3-kinase inhibitor, such as alpelisib.
[0019] In one embodiment, the chemotherapy is a CDK (cyclin-dependent kinase) 4/6/ inhibitor, optionally, abemaciclib.
[0020] In one embodiment, the chemotherapy comprises one or more HER of hEGFR (Human epidermal growth factor receptor) inhibitors.
[0021] In one embodiment, the HER inhibitor is selected from RG7116, RG1273 (pertuzumab, Perjeta®), RG3502 (trastuzumab emantasine, T-DMI), RG597 (trastuzumab, HERCEPTIN), RGA201 (RG7160), erlotinib (Tarceva®), dacomitinib (PF-00299804), PF- 05280014 (Pfizer’s biosimilar mAB to RG597).
[0022] In various embodiments, the chemotherapy regiment comprises two or more HER inhibitors, such as trastuzumab and pertuzumab, and one or more chemotherapy agents, such as, a taxane like docetaxel or paclitaxel. In various embodiments, the chemotherapy regiment further comprises a platinum-based antineoplastic such as carboplatin.
[0023] In various embodiments, the chemotherapy regiment comprises a HER inhibitors, such as trastuzumab or pertuzumab, a tyrosine kinase inhibitor, such as neratinib, and a taxane, such as, docetaxel or paclitaxel. In various embodiments, the chemotherapy regiment further comprises a platinum-based antineoplastic such as carboplatin.
[0024] In various embodiments, the chemotherapy regiment is administered once every three weeks.
[0025] In various embodiments, the crofelemer is administered after a subject begins to exhibit symptoms of CID.
[0026] In certain embodiments, the crofelemer is administered for the duration of treatment with the chemotherapy.
[0027] In certain embodiments, the subject is undergoing chemotherapy to treat one or more forms of cancer, such as breast cancer.
[0028] In certain embodiments, the crofelemer is administered until symptoms of CID are ameliorated and then crofelemer is discontinued.
[0029] In various embodiments, the administration comprises: administering about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering about 500 mg per day; administering about 1000 mg per day; administering about 125 mg two times per day; administering about 250 mg two times per day; or administering about 500 mg two times per day of crofelemer, particularly, enterically protected crofelemer formulated as a tablet for oral administration, to a subject in need thereof. In other embodiments, the crofelemer is formulated for oral administration but is not enterically protected, e.g., does not have an enteric coating. In other embodiments, the dosage of the proanthocyanidin polymer composition is bioequivalent to about 250 mg to about 1000 mg per day; about 250 mg per day; about 500 mg per day; about 1000 mg per day; about 125 mg two times per day; about 250 mg two times per day; or about 500 mg two times per day of an oral dosage form of crofelemer that enterically protected.
[0030] In one aspect, presented herein are methods of treating stool consistency in a subject undergoing chemotherapy, comprising: administering about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering about 500 mg per day; administering about 1000 mg per day; administering about 125 mg two times per day; administering about 250 mg two times per day; or administering about 500 mg two times per day of crofelemer, particularly, enterically protected crofelemer formulated as a tablet for oral administration, to a subject in need thereof (or is a dosage of a proanthocyanidin polymer composition that is bioequivalent to the dosage of an enteric protected formulation of crofelemer).
[0031] In one aspect, presented herein are methods of improving stool consistency in a subject undergoing chemotherapy, comprising: administering about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering about 500 mg per day; administering about 1000 mg per day; administering about 125 mg two times per day; administering about 250 mg two times per day; or administering about 500 mg two times per day of crofelemer, particularly, enterically protected crofelemer formulated as a tablet for oral administration, to a subject in need thereof (or is a dosage of a proanthocyanidin polymer composition that is bioequivalent to the dosage of an enteric protected formulation of crofelemer).
[0032] In one aspect, presented herein are methods of alleviating watery diarrhea in a subject undergoing chemotherapy, comprising: administering about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering about 500 mg per day; administering about 1000 mg per day; administering about 125 mg two times per day; administering about 250 mg two times per day; or administering about 500 mg two times per day of crofelemer, particularly, enterically protected crofelemer formulated as a tablet for oral administration, to a subject in need thereof (or is a dosage of a proanthocyanidin polymer composition that is bioequivalent to the dosage of an enteric protected formulation of crofelemer).
[0033] In one aspect, presented herein are methods of decreasing the number of bowel movements per day in a subject undergoing chemotherapy, comprising: administering about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering about 500 mg per day; administering about 1000 mg per day; administering about 125 mg two times per day; administering about 250 mg two times per day; or administering about 500 mg two times per day of crofelemer, particularly, enterically protected crofelemer formulated as a tablet for oral administration, to a subject in need thereof (or is a dosage of a proanthocyanidin polymer composition that is bioequivalent to the dosage of an enteric protected formulation of crofelemer).
[0034] The dosages may be the amount of a composition containing a proanthocyanidin polymer composition from C. lechleri that is bioequivalent to the dose of an enteric protected formulation of crofelemer.
[0035] In one embodiment, a human subject is considered treated if the subject demonstrates one or more of a decrease in the number of bowel movements per day, a decrease in the number of watery bowel movements per day, an improvement in the daily or weekly abdominal score for pain or discomfort, an improvement in the score for daily stool consistency, a decrease in stool consistency score (from watery to formed), a decrease in the number of days per week that subjects experienced urgency, a decrease in the number of days per week that the subject experienced fecal incontinence.
[0036] In one embodiment, a human subject is considered treated if the subject demonstrates an improvement in the score for daily stool consistency.
[0037] In one embodiment, a human subject is considered treated if the subject demonstrates a decrease in stool consistency.
[0038] In one embodiment, a human subject is considered treated if the subject demonstrates a decrease in the number of watery bowel movements per day.
[0039] In one embodiment, a human subject is considered treated if the subject demonstrates a decrease in the number of bowel movements per day.
[0040] In one embodiment, symptoms increased or decreased are measured from a baseline.
[0041] In one embodiment, the administering is for the duration of the chemotherapy.
[0042] In one embodiment, the administering occurs for about 1 to about 6 weeks longer than the chemotherapy cycle.
[0043] In one embodiment, the administering occurs for about 3 to 12 weeks.
[0044] Other embodiments are disclosed below.
DETAILED DESCRIPTION
[0045] Certain chemotherapies may cause chemotherapy-induced diarrhea (CID) is a human subject that may cause distress, adversely impact the subject’s health and wellbeing, make the chemotherapy difficult to tolerate such that the subject has to take a lower dose or go off of the chemotherapeutic agent or switch to a different treatment regimen that may be, but for the CID, more effective for the treatment of cancer. Proanthocyanidin polymer
compositions of C. lechleri, particularly, crofelemer, and more particularly, enteric coated crofelemer formulated for oral administration, but also SB300, reduce, ameliorate, prevent or eliminate the CID symptoms in a subject undergoing chemotherapy. Thus, administration of crofelemer, or other proanthocyanidin polymer composition of C. lechleri may permit subjects to tolerate either certain chemotherapeutic regimens, or to tolerate higher, more effective, doses of certain chemotherapeutic regimens.
[0046] The methods disclosed herein involved the administration of effective amounts of a proanthocyanidin polymer, e.g., crofelemer, to subjects undergoing chemotherapy having, for example, chemotherapy-induced diarrhea (CID) or at risk of developing CID.
I. Definitions
[0047] Where a term is provided in the singular, the inventors also contemplate aspects of the invention described by the plural of that term. As used in this specification and in the appended claims, the singular forms "a", "an" and "the" include plural references unless the context clearly dictates otherwise, e.g., "a compound" includes a plurality of compounds. Thus, for example, a reference to "a method" includes one or more methods, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure.
[0048] “Ameliorate,” “amelioration,” “improvement” or the like refers to, for example, a detectable improvement or a detectable change consistent with improvement that occurs in a subject or in at least a minority of subjects, e.g., in at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 100% or in a range between about any two of these values. Such improvement or change may be observed in treated subjects as compared to subjects not treated with crofelemer, where the untreated subjects have, or are subject to developing, the same or similar disease, condition, symptom or the like. Amelioration of a disease, condition, symptom or assay parameter may be determined subjectively or objectively, e.g., self-assessment by a subject(s), by a clinician's assessment or by conducting an appropriate assay or measurement. Amelioration may be transient, prolonged or permanent or it may be variable at relevant times during or after crofelemer is administered to a subject or is used in an assay or other method described herein or a cited reference, e.g., within timeframes described infra, or about 1 hour after the administration or use of crofelemer
to about 7 days, 2 weeks, 28 days, or 1, 3, 6, 9 months or more after a subject(s) has received such treatment.
[0049] The “modulation” of, e.g., a symptom, level or biological activity of a molecule, or the like, refers, for example, that the symptom or activity, or the like is detectably increased or decreased. Such increase or decrease may be observed in treated subjects as compared to subjects not treated with crofelemer, where the untreated subjects have, or are subject to developing, the same or similar disease, condition, symptom or the like. Such increases or decreases may be at least about 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 100%, 150%, 200%, 250%, 300%, 400%, 500%, 1000% or more or within any range between any two of these values. Modulation may be determined subjectively or objectively. Modulation may be transient, prolonged or permanent or it may be variable at relevant times during or after crofelemer is administered to a subject or is used in an assay or other method described herein or a cited reference, e.g., within times descried infra, or about 1 hour of the administration or use of crofelemer to about 2 weeks, 28 days, 3, 6, 9 months or more after a subject(s) has received crofelemer.
[0050] As used herein, “subject” includes an animal, including a human, undergoing chemotherapy and having or being at risk for CID or who could otherwise benefit from the administration of crofelemer as described herein, such as a human subject.
[0051] The language “a therapeutically effective amount” of a compound refers to an amount of crofelemer which is effective, upon single or multiple dose administration to the subject, in treating, managing, or ameliorating the symptoms of the chemotherapy induced diarrhea.
[0052] The language “a prophylactically effective amount” of a compound refers to an amount of crofelemer which is effective, upon single or multiple dose administration to the subject, in preventing CID.
[0053] The term “administration” or “administering” includes routes of introducing crofelemer to a subject to perform its intended function. Examples of routes of administration that may be used include injection, oral, inhalation, vaginal, rectal and transdermal. The pharmaceutical preparations may be given by forms suitable for each administration route. For example, these preparations are administered in tablet or capsule form, by injection, inhalation, ointment, or suppository. Administration may also be by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administration is preferred. Depending on the route of
administration, crofelemer can be coated with or disposed in a selected material to protect it from natural conditions that may detrimentally affect its ability to perform its intended function. Crofelemer can be administered alone, or in conjunction with either another agent or agents as described above or with a pharmaceutically-acceptable carrier, or both. Exemplary enteric coated forms of crofelemer are described in, for example, US Patent 7,556,831.
[0054] Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.
[0055] The phrase “pharmaceutically acceptable” refers to crofelemer as described herein, compositions containing crofelemer, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
[0056] The phrase “pharmaceutically-acceptable carrier” includes pharmaceutically- acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject chemical from one organ, or portion of the body, to another organ, or portion of the body.
[0057] The term “treat” or “treatment” as used herein is intended to include the reduction or amelioration of the progression, severity, and/or duration of a condition or one or more symptoms caused by chemotherapy or resulting from the administration of one or more therapies.
[0058] For example, treating CID may include an improvement of the following symptoms of CID, including, for example, a decrease in the number of bowel movements per day (frequency), a decrease in the number of watery bowel movements per day, a decrease in symptom frequency (urgency, fecal incontinence), a decrease in symptom severity (abdominal pain or discomfort), a decrease in daily stool consistency score (watery to formed), or a decrease in stool consistency leading to formed stools from watery stools. The severity of chemotherapy induced diarrhea may be characterized according to Common Toxicity Criteria for diarrhea, adapted from the National Cancer Institute (see, e.g., Stein et al, Ther. Adv. Med. Oncol. 2:51-43 (2010). In this criteria, Grade 1 is an increase of greater than 4 stools per day over baseline (or mild increase in ostomy output compared to baseline); Grade 2 is an increase
of 4 to 6 stools per day over baseline (moderate increase in ostomy output compared to baseline); Grade 3 is an increase in greater than 7 stools per day over baseline, with incidences of incontinence and hospitalization indicated (severe increase in ostomy output compared to baseline); and Grade 4 is life-threatening consequences with urgent intervention indicated. Thus, treatment may include reduction in one, two or three grades of the criteria.
[0059] The term “obtaining” as in “obtaining crofelemer” is intended to include purchasing, synthesizing, isolating, extracting or otherwise acquiring crofelemer.
[0060] The term “tolerate” or “tolerance” as in tolerating a particular chemotherapeutic agent means that the subject does not suffer side effects so severe that they compromise the health and wellbeing of the subject to such an extent that the detriment outweighs the benefit of the chemotherapy or the subject is non-compliant with the chemotherapeutic regimen due to the side effects.
II. Active Compounds
A. Proanthocyanidins
[0061] Proanthocyanidins are a group of condensed tannins. Crude extracts from medicinal plants, for example, Pycanthus angolenis and Baphia nitida, have been shown to have anti diarrheal qualities in animal tests (Onwukaeme and Anuforo, 1993, Discovery and Innovation, 5:317; Onwukaeme and Lot, 1991, Phytotherapy Res., 5:254). Crude extracts which contain tannins, in particular extracts from carob pods and sweet chestnut wood, have been proposed as treatments or prophylactics (U.S. Pat. No. 5,043,160; European Patent No. 481,396).
[0062] Proanthocyanidins are comprised of at least two or more monomer units that may be of the same or different monomeric structure. The monomer units (generally termed "leucoanthocyanidin") are generally monomeric flavonoids which include catechins, epicatechins, gallocatechins, galloepicatechins, flavanols, flavonols, and flavan-3,4-diols, leucocyanidins and anthocyanidins. Therefore, the polymer chains are based on different structural units, which create a wide variation of polymeric proanthocyanidins and a large number of possible isomers (Hemingway et al, 1982, J. C. S. Perkin, 1: 1217). Larger polymers of the flavonoid 3-ol units are predominant in most plants, and are found with average
molecular weights above 2,000 daltons, containing 6 or more units (Newman et al, 1987, Mag. Res. Chem., 25:118).
[0063] Proanthocyanidin polymers are found in a wide variety of plants, particularly those with a woody habit of growth (e.g., Croton spp. and Calophyllum spp.). A number of different Croton tree species, including Croton sakutaris, Croton gossypifolius, Croton palanostima, Croton lechleri, Croton erythrochilus and Croton draconoides, found in South America, produce a red viscous latex sap called Sangre de Drago or "Dragon's Blood". U.S. Pat. No. 5,211,944 first described the isolation of an aqueous soluble proanthocyanidin polymer composition from Croton spp. and the use of the composition as an antiviral agent (See also Ubillas et al, 1994, Phytomedicine, 1:77). The proanthocyanidin polymer composition was shown to have antiviral activity against a variety of viruses including, respiratory syncytial, influenza, parainfluenza and herpes viruses. U. S. Pat. No. 5,211,944 also discloses the isolation of an aqueous soluble proanthocyanidin polymer composition from Calophyllum inophylum and the use of this composition as an antiviral agent.
[0064] Exemplary proanthocyanidin polymer compositions useful in the methods presented herein are preferably isolated from a Croton spp. or Calophyllum spp. by any method known in the art. For example, the proanthocyanidin polymer composition may be isolated from a Croton spp. or Calophyllum spp. by the method disclosed in U.S. Pat. No. 5,211,944 or in Ubillas et al, 1994, Phytomedicine 1: 77-106.
[0065] In one specific embodiment, a proanthocyanidin polymer composition useful in the methods presented herein is crofelemer.
[0066] Crofelemer is an oligomeric proanthocyanidin extracted and purified from the red, viscous latex of the plant Croton lechleri of the family Euphorbiace. The plant is widely distributed throughout tropical Central America and South America and is widely recognized by ethnobotanists and local healers for its medicinal properties (McRae 1988), including for the treatment of diarrhea. Crofelemer is believed to exert its anti-diarrhea effect through luminal blockade of CFTR (cystic fibrosis transmembrane conductance regulator) chloride (Cl- ) channel. Crofelemer has demonstrated in vitro activity against cholera toxin, forskolin, E coli LT and STa toxin-mediated Cl- secretion, and to normalize electrolyte and fluid accumulation in CT-treated mice (Gabriel 1999, Fischer 2004, Adam 2005) via its effects on the CFTR
channel. Crofelemer also significantly improved the secretory diarrhea in humans due to enterotoxigenic E. coli (DiCesare 2002), which is also thought to evoke secretory diarrhea through activation of CFTR (Kunzelmann 2002). Blockade of the CFTR channel could be anticipated to have negative consequences in man, even mimicking cystic fibrosis. However, crofelemer has virtually no systemic bioavailability in humans. When studied, the results indicated that there was little or no absorption of crofelemer from the GI tract, and that crofelemer was well tolerated by normal male subjects. Thus, the site of action of crofelemer is topical in the gastrointestinal tract.
[0067] Crofelemer (CAS 148465-45-6) is an oligomeric proanthocyanidin of varying chain lengths derived from the Dragon's Blood Croton lecheri of the family Euphorbiaceae. Crofelemer has an average molecular weight of between approximately 1500 daltons and approximately 2900 daltons. The monomers comprising crofelemer comprise catechin, epicatechin, gallocatechin, and epigallocatechin. The chain length of crofelemer ranges from about 3 to about 30 units with an average chain length of about 8 units. The structure of crofelemer is shown below.
Wherein the average n=6.
[0068] Another method for isolating crofelemer can be found in U.S. Patent Publication No. 2005/0019389, the contents of which are expressly incorporated herein.
[0069] In addition, the proanthocyanidin polymer composition may be SB 300, as described, for example, by Fischer, H. et al, (2004, J. Ethnopharmacol. , 93(2-3):351-357). SB300 is a natural product extract that is particularly amenable for use in a non-enterically coated or protected formulations and compositions. In an embodiment, a pharmaceutically acceptable composition comprising a proanthocyanidin polymer from Croton lechleri and employed in the treatment methods of the invention can be obtained from C. lechleri, e.g., as described in WO 00/47062 to Shaman Pharmaceuticals, Inc., the contents of which are incorporated herein, and formulated as a food or dietary supplement or nutraceutical formulation, especially in a non-enterically coated formulation.
[0070] In other embodiments, a raw latex obtained from a Croton species or a Calophyllum species or an extract obtained from a Croton species or a Calophyllum species are useful in the methods presented herein. Exemplary extracts are described in Persinos et al., 1979, J. Pharma. Sci. 68:124 and Sethi, 1977, Canadian J. Pharm. Sci. 12:7.
B. Combinations with Chemotherapy Agents
[0071] The proanthocyanidins described herein may be combined with cancer drugs/chemotherapy agents for use in the methods described herein to treat CID. Cancer Drugs and Cancer Chemotherapeutic Agents are general terms with a meaning that includes the terms cancer drug, cancer chemotherapeutic drugs, cancer agent, cancer chemotherapy, chemotherapeutic drug, chemotherapeutic agent, chemotherapy, chemotherapy drug, cancer compound, cancer compound therapy, chemotherapy compound, and cancer drug therapies. Such chemotherapies shall also mean chemical substances that: may inhibit cancer cellular pathways; that may be used to kill cancer cells in vitro; that may be used to kill cancer cells in vivo, as in cancer tumors; and in some cases may be used to treat a person suffering cancer to protect viability of the cancer patient’s normal cells or attack the viability of the cancer patient’s cancer cells.
[0072] By way of serving only as examples without intending to limit the scope of the present invention, and to more particularly point out the practice of the present invention are the following examples and combination uses of the chemotherapy agents. A number of
cellular pathways that may be targeted by chemotherapy agents are also listed. Generally a cancer chemotherapeutic drug is used in the form of a pharmaceutical composition, for a pharmaceutical use, or in a method of treatment of as patient.
[0073] Examples of cellular targets at which a cancer drug may have an effect are listed here, but are not limiting. The cellular targets of cancer chemotherapeutic agents include the following identified targets: mTORC, RAF kinase, MEK kinase, Phosphoinositol kinase 3, Fibroblast growth factor receptor, Multiple tyrosine kinase, Human epidermal growth factor receptor, Vascular endothelial growth factor, Other angiogenesis factors, Heat shock protein; Smo (smooth) receptor, FMS-like tyrosine kinase 3 receptor, Apoptosis protein inhibitor, Cyclin dependent kinases, Deacetylase, ALK tyrosine kinase receptor, Serine/threonine- protein kinase Pim-1, Porcupine acyltransferase, Hedgehog pathway, Protein kinase C, mDM2, Glypciin 3, ChKl, Hepatocyte growth factor MET receptor, Epidermal growth factor domain-like 7, Notch pathway, Src -family kinase, DNA methyltransferase, DNA intercalators, Thymidine synthase, Microtubule function disruptor, DNA cross-linkers, DNA strand breakers, DNA alkylators, JNK-dependent p53 Seri 5 phosphorylation inducer, DNA topoisomerase inhibitors, Bcl-2, and free radical generators.
[0074] In various embodiments, the chemotherapy agent is selected from alkylating agents, anthracyclines, cytoskeletal disruptors (taxanes), epothilones, histone deacetylase inhibitors, inhibitors of topoisomerase I, inhibitors of topoisomerase II, kinase inhibitors, nucleotide analogs and precursor analogs, peptide antibiotics, platinum-based agents and retinoids.
[0075] In particular embodiments, the chemotherapy agent is a cancer growth inhibitor. Cancer growth inhibitors are a type of biological therapy and include tyrosine kinase inhibitors and HER2 inhibitors, proteasome inhibitors, mTOR inhibitors, PI3K inhibitors, histone deacetylase inhibitors and hedgehog pathway blockers.
[0076] In a particular embodiment, the chemotherapeutic agent is one or more tyrosine kinase inhibitors (TKI).
[0077] Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades. The proteins are activated by adding a phosphate group to the
protein (phosphorylation). Tyrosine kinase inhibitors (TKI) are typically used as anti-cancer drugs. TKIs operate by four different mechanisms: they can compete with adenosine triphosphate (ATP), the phosphorylating entity, the substrate or both or can act in an allosteric fashion, namely bind to a site outside the active site, affecting its activity by a conformational change. TKIs are small molecular weight inhibitors of tyrosine phosphorylation, which do not inhibit protein kinases that phosphorylate serine or threonine residues and can discriminate between the kinase domains of the EGFR and that of the insulin receptor. It was further shown that in spite of the conservation of the tyrosine-kinase domains one can design and synthesize TKIs that discriminate between even closely related protein tyrosine kinases such as EGFR and its close relative HER2.
[0078] Specific examples of tyrosine kinase inhibitors include lapatinib, sunitinib, sorafenib, erlotinib, gefitinib, axitinib, imatinib, nilotinib, dasatinib, cabozantinib, ruxolitinib, neratinib, bosutinib and valatinib.
[0079] In a particular embodiment, the chemotherapeutic agent is one or more HER (Human epidermal growth factor receptor) inhibitors.
[0080] Signaling pathways activated by HER2 include: mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K/Akt), phospholipase C g, protein kinase C (PKC) and signal transducer and activator of transcription (STAT). Signaling through the ErbB family of receptors promotes cell proliferation and opposes apoptosis, and therefore must be tightly regulated to prevent uncontrolled cell growth from occurring. Amplification or over-expression of the ERBB2 gene is strongly associated with increased disease recurrence and a poor prognosis. Over-expression is also known to occur in breast, ovarian, stomach, and aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma. HER2 is co-localized, and, most of the time, co-amplified with the gene GRB7, which is a proto-oncogene associated with breast, testicular germ cell, gastric, and esophageal tumors. HER2 proteins have been shown to form clusters in cell membranes that may play a role in tumorigenesis. Specific examples of HER (human epidermal growth factor receptor) inhibitors include RG7116, RG1273 (pertuzumab, Perjeta®), RG3502 (trastuzumab emantasine, T-DMI), RG597 (trastuzumab, HERCEPTIN), RGA201 (RG7160), erlotinib (Tarceva®), dacomitinib (PF- 00299804), PF-05280014 (Pfizer’s biosimilar mAB to RG597).
[0081] Generic names of cancer chemotherapeutic drugs that have been typically used in cancer patients include: doxorubicin, epirubicin; 5-fluorouracil, paclitaxel, docetaxel, cisplatin, bleomycin, melphalan, plumbagin, irinotecan, mitomycin-C, and mitoxantrone. By way of example, some other cancer chemotherapeutic drugs that may be used and may be in stages of clinical trials include: resminostat, tasquinimod, refametinib, lapatinib, Tyverb, Arenegyr, pasireotide, Signifor, ticilimumab, tremelimumab, PrevOnco, ABT-869, bnifanib, tivantinib, Tarceva, erlotinib, Stivarga, regorafenib, fluoro-sorafenib, brivanib, liposomal doxorubicin, lenvatinib, ramucirumab, peretinoin, Ruchiko, muparfostat, Teysuno, tegafur, gimeracil, oteracil, and orantinib.
[0082] Examples of FDA approved cancer drugs (by generic name) which can be used in the present invention include: sorafenib, regorafenib, imatinib, eribulin, gemcitabine, capecitabine, pazopanib, lapatinib, dabrafenib, sunitinib malate, crizotinib, everolimus, torisirolimus, sirolimus, axitinib, gefitinib, anastrozole, bicalutamide, fulvestrant, rabtrexed, pemetrexed, goseribn acetate, erlotinib, vemurafenib, visiodegib, tamoxifen citrate, paclitaxel, docetaxel, cabazitaxel, oxabplatin, ziv-aflibercept, bevacizumab, trastuzumab, pertuzumab, pantiumumab, taxane, bleomycin, melphalan, plumbagin, camptosar, mitomycin-C, doxorubicin, pegylated doxorubicin, 5-fluoro-uracil, temozolomide, pasireotide, tegafur, gimeracil, oteraci, bortezomib, lenabdomide, and romidepsin.
[0083] Manufacturer brand names for some cancer drugs that may be used in the present invention include: NEXAVAR (sorafenb), STIVARGA (regorafenib), AFINITOR (everolimus), GLEEVEC (imatinib), HALAVEN (eribulin), ALIMTA (pemetrexed), GEMZAR (gemcitabine), VOTRIENT (pazopanib), TYKERB (lapatinib), TAFINIAR (dabrafenib), SUTENT (sutinib malate), XALKORI (crizotinib), TORISEL (torisirolimus), INLYTA (axitinib), IRESSA (gefitinib), ARIMIDEX (anastrole), CASODEX (bicalutamide), FASLODEX (fulvestrant), TOMUDEX (rabtrexed), ZOLADEX (goseribn acetate), TARCEVA (erlotininb), XELODA (capecitabine), ZELBROF (vemurafenib), ERIVEDGE (visiodegib), PERJETA (pertuzumab), HERCEPTIN (trastuzumab), TAXOTERE (docetaxel), JEVTANA (cabazitaxel), ELOXATIN (oxabplatin), ZALTRAP (ziv-aflibercept), AVASTIN (bevacizumab) Nolvadex, Istubal, and VALODEX (tamoxifen citrate), TEMODAR (temozolomide), SIGNIFOR (pasireotide), VECTIBIX (pantiumumab), ADRIAMYCIN
(doxorubicin), DOXIL (pegylated doxorubicin), ABRAXANE (Paclitaxel), TEYSUNO (tegafur, gimeracil, oteracil), BORTEZOMIB (Velcade) and with lenalidomide, ISTODAX (romidepsin).
[0084] Cancer drug therapies contemplated for the present invention include Iressa (gefitinib), Arimidex (anastrole), Casodex (bicalutamide), Faslodex (fulvestrant), Tomudex (ralitrexed), Zoladex (goserilin acetate), Nolvadex, Istubal, and Valodex (tamoxifen citrate), Erbitux (cetuximab), Spry cel (dasatinib), Ixempra (ixabepilone), Taxol (paclitaxel), Paraplatin (carboplatin), and Yervoy (ipilumumab), Vectibix (pantiumumab, rilotumumab, trebananib, blinatumumab, Halaven (eribulin), Alimta (pemetrexed), and Gemzar (gemcitabine), Votrient (pazopanib), Tykerb (lapatinib), and Tafmiar (dabrafenib). Doxil (doxorubicin, adriamycin), Temodar (temozolomide), Afmitor (everolimus), Gleevec (imatinib), and Signifor (pasireotide), dovitinib, midostaurin, panobinostat, Teysuno (tegafur, gimeracil, oteracil), navitoclax, velipariban, linifanib, thrombospondin, ilorasertib, elagolix, atrasentan, Sutent (sutinib malate), Xalkori (crizotinib), Torisel (torisirolimus), Inlyta (axitinib), dacomitinib, bosutinib, Tarceva (erlotininb), Xeloda (capecitabine), Zelbrof (vemurafenib), Erivedge (visiodegib), Perjeta (pertuzumab), Herceptin (trastuzumab) Avastin (bevacizumab), Taxotere (docetaxel), Jevtana (cabazitaxel), Eloxatin (oxaliplatin), Zaltrap (ziv-aflibercept), iniparib, neratinib (HKI-272) and ombrabulin.
III. Methods of Treatment
[0085] Provided herein are methods of treating, preventing, or alleviating diarrhea or gastrointestinal symptoms caused by chemotherapy comprising administering to a subject in need thereof an effective amount of crofelemer alone or in combination with a chemotherapy agent. Exemplary diarrhea that can be treated or prevented using the methods presented herein include CID. The subject is preferably a human.
[0086] In one embodiment, treating CID includes an improvement of the following symptoms of CID, including, for example, a decrease in the number of bowel movements per day (frequency), a decrease in the number of watery bowel movements per day, a decrease in symptom frequency (urgency, fecal incontinence), a decrease in symptom severity (abdominal pain or discomfort), a decrease in daily stool consistency score (watery to formed), or a decrease in stool consistency leading to formed stools from watery stools. In certain
embodiments, the treatment results in a reduction in the Grade of the Common Toxicity Criteria for diarrhea, for example, from Grade 4, to Grade 3, Grade 2 or Grade 1; or from Grade 3, to Grade 2 or Grade 1; or from Grade 2 to Grade 1. In certain embodiments, the treatment results in an improvement such that the subject does not meet any of the Common Toxicity Criteria Grades, i.e., is no longer suffering from diarrhea.
[0087] In other specific embodiments, treatment can also include, for example, one or more of a decrease in the number of bowel movements per day, a decrease in the number of watery bowel movements per day, an improvement in the daily abdominal score for pain or discomfort, an improvement in the score for daily stool consistency, a decrease in the number of days per week or per month that subjects experienced urgency, or a decrease in the number of days per week or per month that subjects experienced fecal incontinence.
[0088] In one aspect, provided herein are methods of treating CID in a subject undergoing chemotherapy comprising administering to a subject in need thereof a composition comprising an effective amount of crofelemer to treat CID. In specific embodiments, the crofelemer is an enterically coated oral dosage form. In other embodiments, the crofelemer is an oral dosage form that is not enterically protected.
[0089] In one embodiment, the crofelemer is administered at the same time as chemotherapy to reduce or delay the onset of CID. In one embodiment, the crofelemer is administered before chemotherapy to reduce or delay the onset of CID. In one embodiment, the crofelemer is administered after chemotherapy to reduce the onset of or treat CID.
[0090] CID can be an adverse side effect of chemotherapy, particularly chemotherapy for treatment of cancer. In some embodiments, CID can be severe enough to interfere with the chemotherapy regimen of the subject because of lack of tolerance or reduced tolerance for the chemotherapy regimen due to the CID. In certain embodiments, therefore, provided are methods of increasing the tolerance of a subject for a certain chemotherapy agent or regimen such that the subject can tolerate and can be administered a recommended dosage of a chemotherapeutic agent or can be administered a chemotherapeutic agent.
[0091] In some embodiments, the subject is undergoing chemotherapy to treat one or more forms of cancer. The one or more forms of cancer can be selected from breast cancer, ovarian
cancer, prostate cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer, kidney cancer, thyroid cancer, oral or oropharyngeal cancer, astrocytoma, sarcoma, mesothelioma, meningioma, lymphoma, myeloma, head and neck cancer, lung cancer, carcinoma (e.g., squamous cell carcinoma), malignant melanoma, peritoneal cancer, gastric cancer, hepatic cancer, colorectal cancer, gallbladder cancer, bone cancer, pancreatic cancer, tongue cancer, esophageal cancer, brain tumor, brain stem glioma, a metastases thereof, and leukemia.
[0092] In one embodiment, the chemotherapy comprises one or more tyrosine kinase inhibitors.
[0093] In one embodiment, the tyrosine kinase inhibitor is selected from lapatinib, sunitinib, sorafenib, erlotinib, gefitinib, axitinib, imatinib, nilotinib, dasatinib, cabozantinib, ruxolitinib, neratinib, bosutinib, toceranib, and valatinib.
[0094] In one embodiment, the chemotherapy comprises one or more HER (Human epidermal growth factor receptor) inhibitors.
[0095] In one embodiment, the HER (Human epidermal growth factor receptor) inhibitor is selected from RG7116, RG1273 (pertuzumab, Perjeta®), RG3502 (trastuzumab emantasine, T-DMI), RG597 (trastuzumab, HERCEPTIN), RGA201 (RG7160), erlotinib (Tarceva®), dacomitinib (PF-00299804), PF-05280014 (Pfizer’s biosimilar mAB to RG597).
[0096] In various embodiments, the crofelemer is administered after a subject begins to exhibit symptoms of CID. In various embodiments, the crofelemer is administered prior to the start of chemotherapy or of a round of chemotherapy to prevent or reduce the severity of CID associated with the chemotherapy. In embodiments, the crofelemer is administered for one day, three days, or one week prior to chemotherapy or a round of chemotherapy to prevent or reduce the risk or incidence of CID upon treatment of chemotherapy.
[0097] In certain embodiments, the crofelemer is administered for the duration of treatment with the chemotherapy. The duration of treatment can comprise the time between two chemotherapy rounds. For example, in certain embodiments, chemotherapy is administered once every three weeks or four weeks or once every 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 days.
[0098] In certain embodiments, the crofelemer is administered until symptoms of CID are ameliorated and then crofelemer is discontinued.
[0099] As will be readily apparent to one skilled in the art, the useful in vivo dosage to be administered and the particular mode of administration may vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and/or the specific use for which these compounds are employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods and in consultation with the data presented herein.
[0100] In one aspect, provided herein are methods of treating stool consistency in a subject undergoing chemotherapy, wherein a subject is considered treated if there is an improvement in the score for daily stool consistency and/or a decrease in stool consistency score a measured throughout the day or days or weeks comprising administering to a subject in need thereof a composition comprising an effective amount of crofelemer to treat stool consistency. This decrease may be measured from a baseline. The baseline may be determined in the days to week prior to treatment with crofelemer. Treatment comprises administering about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering 1000 mg per day; administering about 125 mg two times per day; or administering about 500 mg two times per day of crofelemer, preferably an enteric coated oral dosage form, to a subject in need thereof or a dosage of a proanthocyanidin polymer composition (including a non-enteric protected oral dosage form of crofelemer) that is bioequivalent to 250 mg to about 1000 mg per day; about 250 mg per day; 1000 mg per day; about 125 mg two times per day; or about 500 mg two times per day of enteric protected oral dosage form of crofelemer.
[0101] In one aspect, provided herein are methods of alleviating watery diarrhea in a subject undergoing chemotherapy, wherein a subject is considered treated if the subject experiences a decrease in the number of watery bowel movements per day and/or over days, a week or weeks of administration of crofelemer comprising administering to a subject in need thereof a composition comprising an effective amount of crofelemer to alleviate watery diarrhea.
[0102] This decrease may be measured from a baseline. The baseline may be determined in the days to week prior to treatment with crofelemer. Treatment comprises administering
about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering 1000 mg per day; administering about 125 mg two times per day; or administering about 500 mg two times per day of crofelemer, preferably an enteric coated oral dosage form of crofelemer, to a subject in need thereof, or, alternatively, a dosage of a proanthocyanidin polymer composition (including a non-enteric protected oral dosage form of crofelemer) that is bioequivalent to 250 mg to about 1000 mg per day; about 250 mg per day; 1000 mg per day; about 125 mg two times per day; or about 500 mg two times per day of enterically protected oral dosage form of crofelemer.
[0103] In one aspect, presented herein are methods a decreasing the number of bowel movements per day, wherein a subject is considered treated if there is a decrease in the number of bowel movements per day as measured from a baseline comprising administering to a subj ect in need thereof a composition comprising an effective amount of crofelemer to decrease the number of bowel movements per day.
[0104] The baseline may be determined in the days to week prior to treatment with crofelemer. Treatment comprises administering about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering 1000 mg per day; administering about 125 mg two times per day; or administering about 500 mg two times per day of crofelemer, preferably an enteric coated oral dosage form of crofelemer, to a subject in need thereof, or, alternatively, a dosage of a proanthocyanidin polymer composition (including a non-enteric protected oral dosage form of crofelemer) that is bioequivalent to 250 mg to about 1000 mg per day; about 250 mg per day; 1000 mg per day; about 125 mg two times per day; or about 500 mg two times per day of enterically protected oral dosage form of crofelemer.
[0105] In certain embodiments, the methods provided result in a decrease in the Grade of Common Toxicity Criteria Grades for diarrhea. In addition, the methods provided result in increased ability to tolerate the chemotherapeutic regimen such that the subject remains on and is compliant with the prescribed chemotherapeutic regimen.
[0106] Crofelemer may be administered, for example, once a day, twice a day, three times a day, or four times or more often as necessary per day. Crofelemer may be administered in doses, for example of from about between 25 mg BID to about 3000 mg TID, preferably crofelemer is administered from between about 125 mg to about 1000 mg per day. In another
embodiment, crofelemer is administered between 125 mg BID to about 500 mg BID depending of symptoms. In another embodiment, crofelemer is administered as 125 mg BID. In another embodiment, crofelemer is administered as 500 mg BID. Crofelemer may be administered orally, for example, in tablet form, powder form, liquid form or in capsules. In preferred embodiments, the crofelemer is formulated as an enteric coated oral dosage form. In other embodiments, the crofelemer is an oral dosage form that is not enteric coated.
[0107] In exemplary embodiments, the subject is orally administered 250, 500, or 1000 mg/ day of enteric protected crofelemer or is administered a dose of a proanthocyanidin polymer composition, including crofelemer, that is bioequivalent to an oral dosage form of enteric coated crofelemer administered at 250, 500, or 1000 mg/day.
[0108] In specific embodiments, the subject is administered 125, 250 or 500 mg p.o. b.i.d (orally twice per day) enteric coated crofelemer or a dosage of a proanthocyanidin polymer composition bioequivalent to 125, 250 or 500 mg p.o. b.i.d enteric coated crofelemer. Other appropriate dosages for methods may be determined by health care professionals or by the subject. The amount of crofelemer administered daily may be increased or decreased based on the weight, age, health, sex or medical condition of the subject. One of skill in the art would be able to determine the proper dose for a subject based on this disclosure and the data presented in the Examples, which follow.
[0109] In other embodiments, the subject is treated with crofelemer for 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 or more weeks or 26 or more weeks. Length of treatment may vary depending on the type and length of disease and the proper length of treatment may be easily determined by one of skill in the art having the benefit of this disclosure.
[0110] Subjects in need thereof include subjects having or that are susceptible to or who have CID.
[0111] In certain embodiments, the subject is administered crofelemer for treatment of CID in combination with one or more anti-diarrheals, such as, but not limited to, loperamide, octreotide, probiotics and any other agent useful for the treatment of chemotherapy associated diarrhea.
IV. Pharmaceutical Preparations
[0112] Also provided herein are pharmaceutical compositions, comprising an effective amount of a crofelemer described herein and a pharmaceutically acceptable carrier. In a further embodiment, the effective amount is effective to treat CID.
[0113] Examples of the preparation and use of crofelemer have been described in US Patent 7,556,831, US Patent Publication 20070254050 and US Patent Publication 20080031984, all of which are incorporated herein by reference in their entirety.
[0114] One embodiment includes pharmaceutical compositions comprising crofelemer and a pharmaceutically acceptable carrier. In preferred embodiments, the pharmaceutical composition is an enterically protected oral dosage form, such as a tablet or capsule. Alternatively, the pharmaceutical composition is an oral dosage form that is not enterically protected.
[0115] The pharmaceutical compositions described herein may further comprise excipients, for example, one or more of a diluting agent, binding agent, lubricating agent, disintegrating agent, coloring agent, flavoring agent or sweetening agent. Compositions may be formulated for selected coated and uncoated tablets, hard and soft gelatin capsules, sugar- coated pills, lozenges, wafer sheets, pellets and powders in sealed packet. For example, compositions may be formulated for topical use, for example, ointments, pomades, creams, gels and lotions.
[0116] In certain embodiments, these pharmaceutical compositions are suitable for topical or oral administration to a subject. In other embodiments, as described in detail below, the pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposomal preparation or solid particles containing the compound.
[0117] A pharmaceutical carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
[0118] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0119] Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
[0120] Compositions containing crofelemer include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally
be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.01% to about 99% of active ingredient, for example, from about 5% to about 70%, or from about 10% to about 30%.
[0121] Liquid dosage forms for oral or rectal administration of crofelemer may include, for example, pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, com, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
[0122] Suspensions, in addition to crofelemer may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof. Dosage forms for the topical or transdermal administration of crofelemer can include, for example, powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The ointments, pastes, creams and gels may contain, in addition to crofelemer, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays can contain, in addition to a crofelemer, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0123] Examples of suitable aqueous and non-aqueous carriers which may be employed in the pharmaceutical compositions can include, for example, water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by
the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
[0124] In one embodiment, crofelemer is enteric coated so as to protect it from degradation by the acidic conditions of the stomach and/or from interactions with proteins, such as pepsin, present in the stomach, e.g., an enteric protected formulation. In a specific embodiment, crofelemer is in tablet form. In yet another embodiment, the tablet is enteric coated, e.g., Eudragit®. In one embodiment, crofelemer is formulated as an enteric coated bead or granule in an enteric coated capsule shell. In another embodiment, crofelemer is formulated in a delayed release composition.
[0125] In certain embodiments, the composition is formulated with a compound or compounds which neutralize stomach acid. Alternatively, the pharmaceutical composition containing the composition is administered either concurrent with or subsequent to or after administration of a pharmaceutical composition which neutralize stomach acid. Compounds, such as antacids, which are useful for neutralizing stomach acid include, but are not limited to, aluminum carbonate, aluminum hydroxide, bismuth subnitrate, bismuth subsalicylate, calcium carbonate, dihydroxyaluminum sodium carbonate, magaldrate, magnesium carbonate, magnesium hydroxide, magnesium oxide, and mixtures thereof. Compounds that are able to reduce the secretion of stomach acid and/or are able to reduce the acidity of stomach fluid are well known in the art and include, but are not limited to, antacids (aluminum hydroxide, aluminum carbonate, aluminum glycinate, magnesium oxide, magnesium hydroxide, magnesium carbonate, calcium carbonate, sodium bicarbonate), stomach acid blockers and a combination of any of the foregoing. In general, any drug that has been approved for sale by the relevant government agency and is able to reduce the production of stomach acid and/or reduce the acidity of stomach fluid can be administered in combination with an inhibitor molecule, such as crofelemer, in accordance with the methods presented herein.
[0126] In a particular embodiment where crofelemer is not enteric coated, crofelemer is formulated with one or more compounds that are able to reduce the secretion of stomach acid and/or able to reduce the acidity of stomach fluid. In an exemplary embodiment, crofelemer is formulated in a controlled release (delayed release) composition, such as Merck GEM, Alza
OROS, wax matrix (release is primarily delayed until after the formulation passes out of the stomach and into the intestine).
[0127] Also provided herein are pharmaceutical formulations of crofelemer comprising the composition along with a pharmaceutically acceptable carrier, at a dose which is therapeutically effective at treating CID. In one embodiment, a directly compressible crofelemer (e.g., that can be directly compressed, without excipients, into a tablet of pharmaceutically acceptable hardness and friability) compressed into a tablet, optionally with a lubricant, such as but not limited to magnesium stearate, is enteric coated. These formulations can be prepared by methods known in the art, see, e.g. methods described in Remington's Pharmaceutical Sciences, 18th Ed., ed. Alfonso R. Gennaro, Mack Publishing Co., Easton, Pa., 1990.
[0128] In a specific embodiment, the proanthocyanidin polymer composition comprises crofelemer (CAS 148465-45-6).
[0129] In a more another embodiment, a composition is enteric coated. Enteric coatings are those coatings that remain intact in the stomach, but will dissolve and release the contents of the dosage form once it reaches the small intestine. A large number of enteric coatings are prepared with ingredients that have acidic groups such that, at the very low pH present in the stomach, i.e. pH 1.5 to 2.5, the acidic groups are not ionized and the coating remains in an undissociated, insoluble form. At higher pH levels, such as in the environment of the intestine, the enteric coating is converted to an ionized form, which can be dissolved to release the inhibitor molecule. Other enteric coatings remain intact until they are degraded by enzymes in the small intestine, and others break apart after a defined exposure to moisture, such that the coatings remain intact until after passage into the small intestines.
[0130] Polymers which are useful for the preparation of enteric coatings include, but are not limited to, shellac, starch and amylose acetate phthalates, styrene-maleic acid copolymers, cellulose acetate succinate, cellulose acetate phthalate (CAP), polyvinylacetate phthalate (PVAP), hydroxypropylmethylcellulose phthalate (grades HP-50 and HP-55), ethylcellulose, fats, butyl stearate, and methacrylic acid-methacrylic acid ester copolymers with acid ionizable groups. In one embodiment, the pharmaceutical composition contains a polymeric proanthocyanidin composition and the enteric coating polymer Eudragit® L 30D, an anionic
copolymer of methacrylic acid and methyl acrylate with a mean molecular weight of 250,000 Daltons. In another embodiment, the enteric coating polymer is Eudragit® L 30D-55. Application of the enteric coating to the crofelemer composition can be accomplished by any method known in the art for applying enteric coatings. For example, but not by way of limitation, the enteric polymers can be applied using organic solvent based solutions containing from 5 to 10% w/w polymer for spray applications and up to 30% w/w polymer for pan coatings. Solvents that are commonly in use include, but are not limited to, acetone, acetone/ethyl acetate mixtures, methylene chloride/methanol mixtures, and tertiary mixtures containing these solvents. Some enteric polymers, such as methacrylic acid-methacrylic acid ester copolymers can be applied using water as a dispersant. The volatility of the solvent system must be tailored to prevent sticking due to tackiness and to prevent high porosity of the coating due to premature spray drying or precipitation of the polymer as the solvent evaporates.
[0131] In another embodiment, the pharmaceutical composition comprising crofelemer is formulated as enteric coated granules or powder (microspheres with a diameter of 300-5001) provided in either hard shell gelatin capsules or suspended in an oral solution for pediatric administration. The enteric coated powder or granules may also be mixed with food, particularly for pediatric administration.
[0132] The granules and powder can be prepared using any method known in the art, such as but not limited to, crystallization, spray-drying or any method of comminution, for example, using a high speed mixer/granulator. Exemplary formulations may be found, for example, in the following US patents and applications US Patent No. 7,341,744; USSN 11/510,152; and USSN 12/175,131.
[0133] Regardless of the route of administration selected, crofelemer is formulated into pharmaceutically-acceptable dosage forms by methods known to those of skill in the art.
[0134] In combination therapy treatment, both the compounds and the other drug agent(s) are administered to mammals (e.g., humans, male or female) by methods known in the art. The agents may be administered in a single dosage form or in separate dosage forms. Effective amounts of the other therapeutic agents are well known to those skilled in the art. However, it is well within the skilled artisan’s purview to determine the other therapeutic agent’s optimal effective-amount range. In one embodiment in which another therapeutic agent is administered
to an animal, the effective amount of the compound is less than its effective amount in case the other therapeutic agent is not administered. In another embodiment, the effective amount of the agent is less than its effective amount in case the compound is not administered. In this way, undesired side effects associated with high doses of either agent may be minimized. Other potential advantages (including without limitation improved dosing regimens and/or reduced drug cost) will be apparent to those skilled in the art.
[0135] In various embodiments, the therapies (e.g., prophylactic or therapeutic agents) are administered less than 5 minutes apart, less than 30 minutes apart, 1 hour apart, at about 1 hour apart, at about 1 to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, at about 12 hours to 18 hours apart, 18 hours to 24 hours apart, 24 hours to 36 hours apart, 36 hours to 48 hours apart, 48 hours to 52 hours apart, 52 hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84 hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours part. In one or more embodiments, two or more therapies are administered within the same patient’s visit.
V. Kits
[0136] Kits are also provided herein, for example, kits for treating a diarrhea, e.g., CID in a subject undergoing chemotherapy. The kits may contain, for example, crofelemer or a pharmaceutical composition comprising crofelemer and instructions for use. The instructions for use may contain prescribing information, dosage information, storage information, and the like.
[0137] Label instructions include, for example, instructions to take the crofelemer for at least 3 days for the treatment of CID. The instructions could also read, for example, take from between 125mg BID to 500mg BID of crofelemer until resolution of symptoms or for the duration of chemotherapy treatment for treatment of CID. The instructions could also read, for example, take 125mg BID of crofelemer until resolution of symptoms or for the duration of chemotherapy treatment for treatment of CID. The instructions could also read, for example, take 500mg BID of crofelemer until resolution of symptoms of CID.
EXAMPLE
[0138] It should be appreciated that the invention should not be construed to be limited to the example, which is now described; rather, the invention should be construed to include any and all applications provided herein and all equivalent variations within the skill of the ordinary artisan.
Example 1: A Study of the Safety and Effectiveness of Crofelemer for the Treatment of Chemotherapy-Induced Diarrhea in Dogs
[0139] Toceranib phosphate (Palladia®) is a multi -kinase inhibitor targeting several receptor tyrosine kinases (RTK), and is indicated for the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement in dogs. Toceranib phosphate is currently used more often off-label to treat neoplasias other than mast cell tumors.
[0140] Toceranib phosphate is indicated at an initial dosage of 3.25 mg/kg (1.48 mg/lb) body weight, orally every other day. Dose reduction intervals of 0.5 mg/kg [to a minimum dose of 2.2 mg/kg (1.0 mg/lb) every other day] and dose interruptions (cessation of toceranib phosphate for up to two weeks) may be utilized, if needed, to manage adverse reactions. This approval was based upon a randomized, placebo-controlled, double-masked, multicenter clinical field study showing a statistically significant advantage for toceranib phosphate over placebo (37% vs. 8%, p<0.001) in the primary effectiveness endpoint of objective response at the end of the six- week masked phase (London CA, et al, Clin. Cancer Res, 15(11), 2009). Toceranib phosphate is sometimes prescribed at a lower dose (2.5-3 mg/kg/dose) than the labeled dose; however, adverse effects of diarrhea are still observed, although generally with a lower frequency.
[0141] It is not expected that any increase in adverse reactions would be noted with the combination of crofelemer and toceranib phosphate over toceranib phosphate alone, since crofelemer is minimally absorbed and has been demonstrated in human studies to have minimal interaction on pharmacologic exposure of other drugs.
[0142] Toceranib phosphate has been associated with severe diarrhea or GI bleeding that requires prompt treatment. During the masked phase of the London study, 46% all grade and 7% grade 3-4 diarrhea was observed on toceranib phosphate vs. 27% all grade and 3% grade 3-4 diarrhea on placebo. During the masked plus open label phases of the study, 59% any grade and 8% grade 3-4 diarrhea was observed with toceranib phosphate. Dose interruptions and dose reductions are considered necessary depending upon the severity of clinical signs.
[0143] Crofelemer (SP-303) is a proanthocyanidin molecule purified from the tree Croton lechleri that has strong anti-secretory properties and a unique mode of action through modulation and normalization of hyperactivity of both cAMP-stimulated CFTR channels and calcium- activated chloride channels (CaCC). Crofelemer treats diarrhea without affecting intestinal motility in several species including dogs and humans. Crofelemer is not absorbed systemically at the therapeutic dose, but instead acts locally within the lumen of the gastrointestinal tract.
[0144] Crofelemer is approved by the FDA (CDER) for the treatment of non-infectious diarrhea in humans with HIV who are being treated with anti-retrovirals. The approval supports chronic administration of crofelemer.
[0145] Crofelemer is being studied to treat acute diarrhea in dogs. In a proof-of-concept study (CANA-001), crofelemer (2 - 4 mg/kg twice daily for three days; n = 29) or placebo (twice daily for three days; n = 32) was administered to dogs exhibiting acute diarrhea. After three 24-hour treatment periods and one 24-hour observation period, dogs treated with crofelemer had better resolution of diarrhea than did placebo-treated dogs. An ongoing randomized, placebo-controlled study (CANA-003) is designed to provide substantial evidence of effectiveness of crofelemer for acute diarrhea in dogs.
[0146] A safety and tolerability study of crofelemer dosed at 2 - 4 mg/kg BID for three days was performed in eight dogs on chemotherapy (CANA-002). This was a two-site, open-label, safety study of crofelemer enteric-coated tablet in client-owned dogs with current (active) diarrhea or a history of CID within 90 days prior to screening (either by previously prescribed medications to treat diarrhea or by signs noted in their medical chart). No serious adverse events (SAEs) were reported during the study, and no subjects withdrew from the study for any reason including AEs or subject safety concerns. No clinically significant safety findings were observed during the study. All eight dogs had a formed stool at the last reported observation.
Study Design
[0147] This study is a prospective, double-blinded, multi-site proof-of-concept study (Table 1).
Table 1. Summary of C-102 experimental design
Study Overview
[0148] This study will be conducted on an out-patient basis, sourcing dogs from referral and academic veterinary centers. A single protocol will be followed at all study sites. Only dogs that have received a minimum of three doses of Palladia® brand name tablets manufactured by Zoetis will be eligible for this study. Due to the possibility that compounded toceranib phosphate may cause more variation in the induction of diarrhea and cause more severe diarrhea, dogs taking compounded toceranib phosphate are not eligible for this study. Palladia® brand name tablets may be obtained from any source that is agreeable to the Investigator and may include the hospital or site pharmacy, a local pharmacy or an online pharmacy.
[0149] Dogs exhibiting diarrhea with a Purina Fecal Score (PFS) of 6 or 7 will be presented by their owner for enrollment in the study. Owners may be informed about this clinical trial at the time their dog begins Palladia® or within approximately 1-12 weeks of starting Palladia®, although only 20-40% of dogs treated with Palladia® will develop clinically significant diarrhea, depending upon dosing. If their dog does develop clinically significant diarrheal signs while taking Palladia®, the owner will be instructed to take a photo of the diarrhea with their cell phone camera and then present their dog for a physical exam. If the Investigator assesses the dog as meeting the enrollment criteria for the study, enrollment will occur.
[0150] Baseline information will include the qualifying PFS (and any photos that the owner has), the time that diarrhea was first noted, the number of diarrhea episodes since the diarrhea began (if known), review of concomitant medications within 72 hours prior to enrollment, medical and medication history, physical examination and collection of samples for clinical pathology testing (CBC, CHEM, U/A, fecal sample for ova and parasites). Dogs meeting all of the inclusion criteria and none of the exclusion criteria will be randomized to receive either the Investigational Veterinary Product (IVP) or Control Product (CP) twice daily (12 ± 2 hours apart) for a total of 6
doses. The first dose should be administered orally in the hospital by the hospital staff immediately following completion of all the screening activities (i.e., the same day).
[0151] The Study Period (TO - T96hr) is divided into three 24-hour Treatment Periods (TO - T24hr; T>24hr - T48hr; T>48hr - T72hr) followed by a 24-hour Observation Period (T>72hr - T96hr), which begins 12 hours following the last treatment (administered at T60h) and continues for 24 hours. Therefore, each dog will be assessed by the owner for a total of 96 hours. Dosing for each dog occurs approximately at TO, T12hr, T24hr, T36hr, T48hr and T60hr. During the Study Period, dogs live at home, and the safety and health of the dogs will be monitored by their owner with daily phone calls between the Investigator or trained designee. These daily calls assess the health status of the dog and ensure that the dog is brought to the Investigator to assess for any possible adverse events.
[0152] Fecal Assessments are completed daily by the owner. Owners are asked to complete a daily diary in which they record the time, the color and one photo of each bowel movement (all elimination within a 15-minute timeframe will be considered a single bowel movement). This allows a single blinded person, to select the appropriate Purina Fecal Score for each bowel movement. Abnormal observations will be reported by the owner which will be assessed by the Investigator or trained designee each day for determination of Adverse Events. Concomitant medications will be reported by the owner and recorded by the study staff during the 96-hour Study Period.
[0153] At the end of the Study Period or at discontinuation, dogs will undergo a final evaluation by the Investigator before completing the study, which will include another physical examination and additional clinical pathology testing (CBC, CHEM). A repeat UA is conducted only if the baseline results were abnormal.
[0154] Data is captured on electronic data capture forms, with paper forms used as a backup. Study Procedures Informed Consent
[0155] Owners are approached by their dog’s treating veterinarian/investigator about participation in this study. Diarrhea associated with Palladia® therapy typically occurs within the first few weeks of starting therapy. Therefore, owners may be approached about this study at the time their dog is started on Palladia® treatment of a malignancy, or within 90 days of
starting Palladia® treatment. This study may be discussed with the dog owner in anticipation of the dog potentially developing diarrhea, with the understanding that many of these dogs will not develop signs of diarrhea and ultimately will not be enrolled in the study. Alternatively, an owner may be presented with this study at the time of first presenting with their dog that already has diarrheal signs. Owners are instructed to take a photo of the diarrhea with their cellular telephone or digital camera. The owners are provided with written and oral information about the study at that time. If an owner agrees to have their dog participate in the study, at the time their dog develops diarrhea per the study requirements, the owner will sign and date an informed consent form (ICF) prior to screening activities.
Screening
[0156] If an owner notes that his/her dog has developed diarrhea after a minimum of three doses of Palladia® brand name tablets, the owner will bring the dog to the study site and the owner and Investigator will discuss the PFS chart and review any photos of diarrhea that the owner may have. If the screening PFS is a 6 or 7, an informed consent must be obtained, and then the Investigator will determine if the dog meets the study inclusion and exclusion criteria. The VCOG-CTCAE vl.l Grade for diarrhea (See Appendix 4) will also be captured at screening. Upon verifying that a dog meets the inclusion criteria and none of the exclusion criteria of the study, a medical history, assessment of previous and current medications, physical exam and collection of samples for clinical chemistry, hematology, urinalysis and fecal analysis will be obtained to establish pre-treatment (baseline) values. Results of the above baseline laboratory assessments will not preclude a dog from being enrolled unless the dog does not meet the inclusion and exclusion criteria of the protocol. Instead, pre-treatment values will be considered baseline findings and recorded on the appropriate CRF.
Time 0
[0157] After the dog has passed screening it is considered eligible for enrollment and is enrolled in the study. The first dose of the study treatment will be administered orally to the dog by the study staff while the dog is still at the study site. The time point for this first dose administration will be recorded and noted as Time 0 (TO). Since dosing is intended to occur approximately every 12 hours, the second dose will be administered at home by the owner on the same day if the first dose was administered before 12 noon, or on the following morning if
the first dose was administered in the afternoon. All subsequent doses will follow the twice daily 12 ± 2 hours apart dosing schedule.
Treatment Period
[0158] Study treatments will be administered orally during the Treatment Period (TOhr - T72hr) twice daily (12 ± 2 hours apart) for three 24-hour Treatment Periods. However, the second dose may be administered up to 18 hours after the first dose if the first dose was administered at the study site during the afternoon. A vehicle such as a Greenies Pill Pocket(TM) may be used for dosing but is not required. Study dogs must remain on Palladia® brand name tablets and not change to compounded toceranib phosphate while on study.
[0159] For each bowel movement noted, the dog owner or his/her designee will take a photo and upload it to a server throughout the subsequent 96 hours from the first dose. If the owner/designee finds that a study dog has had an unwitnessed bowel movement, a photo will be taken at the time the bowel movement is observed, and entered into the EDC as an unwitnessed bowel movement. If multiple bowel movements are noted within a 15-minute time period, they can be considered as one bowel movement and the consistency will be determined based upon the highest PFS score observed and described.
[0160] A daily phone call will be attempted by the study staff to the owner/designee to confirm that the data entered into the EDC by the owner is correct. Every effort will be made by the site staff to speak to the owner/designee at least once within each 24 hour interval. If the site is unsuccessful, the site will note this in the EDC; however, this inability to make telephone contact will not be considered a protocol deviation.
[0161] Upon speaking with the owner/designee, any observations noted by the owner/designee will be assessed by the Investigator as a possible Adverse Event. Additionally, any new medications given to the dog by the owner will be entered into the Prior and Concomitant Medication page.
Observation Period
[0162] During the Observation Period (T>72hr - T96hr), the owner will continue to photograph their dog’s bowel movements but no further dosing of test articles will be done. A daily phone call will be attempted by the study staff to the owner/designee to confirm that the data entered into the EDC by the owner is correct. Any observations noted by the
owner/designee will be assessed by the Investigator as a possible Adverse Event. Additionally, any new medications given to the dog by the owner will be entered into the Prior and Concomitant Medication page. The Observation Period will be used to evaluate persistence of effect or recurrence of diarrheal signs upon withdrawal of IVP.
Final Evaluation (End of Study Procedures)
[0163] A dog will be considered to have completed the study upon successful completion of this visit and its procedures. A final physical exam will be conducted at the end of the Observation Period, or within 3 business days of the end of the Observation Period or at discontinuation (if a dog is discontinued, the site staff will attempt to have the owner bring the dog in to complete this visit. If this is not possible, the dog will be considered lost to follow up). Samples will be collected for clinical chemistry, hematology and urinalysis (urinalysis will be repeated only if the initial sample had clinically significant abnormalities). A final VCOG-CTCAE vl.l Grade for diarrhea will also be assessed at the same time. The Investigator or co-investigator will meet with the dog owner to review and confirm for accuracy the data in the daily diary, and ask about recrudescence of diarrheal signs with emphasis on the color and the frequency of any bowel movements following the completion of IP dosing.
[0164] The study may be terminated (i.e. not completed) at any time at the discretion of the Sponsor. The reason for termination will be documented in the study records.
Study Discontinuation
[0165] A dog may be discontinued from the study by its owner or by the Investigator for any reason and at any time.
[0166] In the event a dog discontinues the study, the same procedures should be conducted that are done at the Final Evaluation. If the reason for discontinuation is due to an AE, this will be documented on the AE form.
Adverse Events
[0167] Any clinically significant changes from the baseline (before treatment with IPs) in the dog’s signs, behavior and fecal attributes will be reported by the dog’s owner. Any clinically significant changes from the baseline in the dog’s physical exam or laboratory values will be noted by the Investigator on the Adverse Event (AE) Form, as appropriate. The assessment of adverse
events will also be ascertained via the daily phone calls between the dog owner and the Investigator or trained designee. Adverse events will be graded according to the ABON System.
Number of Animals
[0168] The enrollment target is at least 25 evaluable cases across all sites on IVP for the primary evaluation of efficacy. At least 12 additional evaluable cases on CP will be enrolled to allow for comparison of efficacy results between IVP and CP. The ratio of IVP to CP-treated dogs will be approximately 2: 1. The Study will use at least three geographically diverse sites across the contiguous United States. The maximum enrollment for any given site is 40% of the total number of evaluable cases in the study.
[0169] As this is a pilot study, the sample size estimation is not based on statistical considerations. An evaluable sample size of at least 25 evaluable cases on IVP and 12 evaluable cases on CP is considered sufficient for the purposes of this study.
Blocking Factors
[0170] No blocking factors will be utilized in this study.
Randomization Procedures
[0171] A separate randomization list will be created for each study site by the Study Statistician. The Statistician will randomly allocate study treatments at a ratio of approximately 2: 1 IVP: CP.
Blinding Procedures
[0172] This is a randomized, double-blinded study, therefore the Sponsor, the owner, the Investigator and all site study staff will be blinded to treatment. Owners will additionally be blinded to the previous recordings of their dog’s bowel movements in the online data capture system so as not to influence their subsequent recording of bowel movements.
INVESTIGATIONAL PRODUCTS (IP)
Investigational Veterinary Product (IVP)
Proprietary Name: Crofelemer (CAS Number: 148465-45-6 )
[0173] The IVP formulation will be manufactured according to the principles of GMP. A certificate of analysis for each formulation will be included in the final study report. The
manufacturing site name and address, percent composition, lot/batch number, and expiry/retest date will be documented.
[0174] In addition to the active pharmaceutical ingredient (API) of crofelemer, the inactive ingredients include microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate. The enteric-coating ingredients include ethylacrylate and methylacrylate copolymer dispersion, talc, triethyl citrate, xanthan gum, titanium oxide, propyl paraben and methyl paraben.
Dosage Form
[0175] The IVP will be supplied as unscored enteric-coated white tablets containing 125 mg of crofelemer.
Control Product (CP)
[0176] The CP will be manufactured according to the principles of GMP. A certificate of analysis will be included in the final study report. The manufacturing site name and address, percent composition, lot/batch number, and expiry/retest date will be documented.
[0177] The formulation of the CP will match that of the IVP but will not contain the active pharmaceutical ingredient (API).
Dosage Form
[0178] The CP will be supplied as unscored enteric-coated white tablets of the same size as the IVP containing 0 mg crofelemer.
Dose Justification
[0179] The dose for this study was based on data obtained from a pilot study that assessed the clinical effectiveness of crofelemer (SP-303) in alleviating clinical signs associated with secretory diarrhea in dogs (CANA-001) and the wide margin of safety established in 30-day (WIL-288006) and 9-month (WIL-288022) toxicity studies. Chronic safety of crofelemer in dogs was studied in a 9-month study during which tablets were administered in capsules once daily, 7 days per week, for 273 or 274 days to three groups of beagle dogs. Dosage levels were 50, 175 and 600 mg/kg/day, plus a concurrent control group. Based on the results of this study, the no-observed-adverse-effect level (NOAEL) for oral (capsule) administration of enteric-coated crofelemer tablets to dogs for 273 or 274 consecutive days was 50 mg/kg/day. At this dose level, findings were restricted to
infrequent gastrointestinal signs. The results at the higher dosages (175 and 600 mg/kg/day) suggested that the primary adverse effect was gastrointestinal irritation, which in turn caused a variety of secondary effects (decreased body weight and food consumption, diarrhea, emesis, changes in hematology and serum chemistry parameters, decreased thyroid/parathyroid weights and/or macrophage infiltration with the presence of basophilic bodies and the uptake of pigment in the lymph nodes, gastrointestinal tract and liver). Thus, the no effect level is estimated to be between 50 and 175 mg/kg/day.
Safety Precautions for Study Personnel
[0180] Standard precautions for the safety of study personnel will be followed during the study. There are no special precautions for the dog owner to be aware of when administering the IPs. A safety data sheet (SDS) will be provided to the Site with each shipment of IPs.
INVESTIGATIONAL PRODUCTS ADMINISTRATION
[0181] A study initiation meeting will be held for each participating study site (either in- person or by webinar) to ensure that the Investigator and associated study personnel have a thorough understanding of the procedures and can explain such procedures to the dog owner regarding administration of IPs and collection of data.
[0182] At the time of study enrollment for each dog, the dog will be weighed and the Investigator will determine the dose from the following table:
Table 2: Dosage based on body weight
[0183] The first dose of the study treatment will be administered orally to the dog by the study staff while the dog is still at the study site. Dogs will then be dosed at home orally twice daily (12 ± 2 hours apart) by their owner or designee for the remainder of the study. The dog owner will record the time of dose administration during the study. A vehicle such as a Greenies Pill Pocket™ may be used or a small ball of food, but is not required. After the dose has been administered, the dog will be observed briefly to ensure the tablet(s) have been swallowed and not spit out.
[0184] If a dog vomits within one hour after dosing, this observation will be recorded by the owner and the dog should be re-dosed with the same number of new tablets. If a dog vomits more
than one hour after dosing, this observation should be recorded by the owner, but the dog should not be re-dosed at that time and will be considered dosed for that time point. If a dog vomits more than once after dosing, the dog should be discontinued from the study. The Investigator or designee will record each vomiting episode on the Adverse Event CRF.
Table 3: Test Animals And Case Identification
[0185] A unique case number will be assigned to each dog enrolled in the study but no case number will be assigned to dogs whose owners sign an ICF but whose dogs are not formally screened and enrolled. At each site, case numbers will consist of a two-digit site identification number followed by a three-digit dog identification number. IPs will be dispensed to the owners based on the sequential numbering of each enrolled dog.
EFFECTIVENESS VARIABLES
Primary Endpoint
Resolution of Diarrhea
[0186] Treatment success (resolution of diarrhea) will be defined as any dog that develops formed stool (PFS of 1, 2, 3, 4 or 5) and maintains formed stool (i.e. - no PFS of 6 or 7) or has no stool, for at least 24 hours during the Treatment Period (TOhr - T72hr). Therefore, resolution of diarrhea must occur by T48hr.
[0187] A treatment failure will be defined as any dog that does not achieve a formed stool (PFS of 1, 2, 3, 4 or 5) for at least 24 hours during the Treatment Period (TOhr - T72hr), and/or any of the following is experienced:
[0188] 1. Withdrawal of Owner Consent due to perceived lack of efficacy
[0189] 2. Adverse event that prevents its continued participation in the study
Secondary Endpoints
Resolution of Diarrhea over the entire Treatment Period
[0190] Treatment success (resolution of diarrhea) will be defined as any dog that develops formed stool (PFS of 1, 2, 3, 4 or 5) and maintains formed stool (i.e. - no PFS of 6 or 7) or has no stool, during the Treatment Period (TOhr - T72hr).
[0191] A treatment failure will be defined as any dog that does not achieve a formed stool (PFS of 1, 2, 3, 4 or 5) during the Treatment Period (TOhr - T72hr), and/or any of the following is experienced:
[0192] 1. Withdrawal of Owner Consent due to perceived lack of efficacy
[0193] 2. Adverse event that prevents its continued participation in the study
12.2.2 Comparison of Diarrhea VCOG-CTCAE yl.1 Grade at Screening and at Final Evaluation
[0194] The VCOG-CTCAE vl.1 Grade for diarrhea taken at Screening for each dog will be compared to the VCOG-CTCAE vl. l Grade for diarrhea taken at T72h, T96h and at Final Evaluation. The change in Grade between Screening and T72h, T96h and the Final Evaluation will be compared between the dogs that received IVP and the dogs that were given CP.
Time to Last Unformed Stool
[0195] Time to the last unformed stool (TLUS) will be determined by the elapsed time between the first dose (TOhr) and the last unformed stool (PFS of 6 or 7) during the 72-hour Treatment Period only (TOhr - T72hr).
Frequency of Loose or Watery Diarrhea
[0196] The frequency of loose or watery diarrhea (PFS of 6 or 7) will be determined by the total number of unformed stool episodes (PFS of 6 or 7) occurring during the Study Period: TOhr - T96hr. (To be analyzed in 24-hour periods.)
Safety
[0197] Safety assessments will be made on the basis of signs reported by the owner as well as physical exam findings made by the Investigator and any abnormalities in laboratory work throughout the study.
Fecal Assessment
Purina Fecal Score (PFS)
[0198] Using the Purina Fecal Scoring (PFS) Chart, a PFS will be obtained at screening via communication with the dog owner and ideally with one or more photos of the dog’s bowel movements. Each daily evaluation of PFS will be described by the dog owner and reviewed by telephone between the dog owner and the Investigator or trained designee.
[0199] Each fecal assessment will only consider new bowel movements produced since the previous fecal assessment. If the dog has experienced two or more bowel movements during a 15- minute period, then these bowel movements will be collectively noted and a single PFS assigned, with the highest PFS numerical score appropriate for the bowel movements recorded on the CRF.
Number of Bowel Movements
[0200] Throughout each day during the Study Period, the dog owner/designee will record each episode of bowel movements with a photo uploaded onto the eCRF. If the dog has experienced two or more bowel movements during a 15 -minute period, then these bowel movements will be collectively noted as one event. After each episode of bowel movements and recording of the time and photo, the next episode of bowel movement(s) will be considered a separate event.
STATISTICAL ANALYSIS
[0201] All statistical tests will be 2-sided. Effectiveness will be evaluated at a 5% significant level. All tests will be performed using SAS version 9.3 or higher.
Statistical Analysis Populations
[0202] As this is a proof-of-concept study, the effectiveness analyses will include all dogs that were randomized and received at least one dose of the study medication (safety population/Intent-to-Treat (ITT) population).
Effectiveness
Primary Effectiveness Variable: Resolution of Diarrhea
[0203] The primary effectiveness variable ‘resolution of diarrhea’ will be dichotomized (success vs failure) and the proportion of success between the treatment groups during the treatment period (T0hr-72hr) will be compared. Possible differences between treatment groups will be assessed by a generalized linear mixed model (using SAS® Proc GLIMMIX assuming a binomial
distribution and logit link). The model will include the fixed effect of Treatment (IVP or CP), Site and Treatment by Site interaction as random effects with baseline PFS as a covariate.
[0204] Treatment effectiveness will be concluded if there is a significant difference in the success rates between the two treatment groups and percent success is higher in the IVP group compared with the CP group.
Secondary Effectiveness Variables
Resolution of Diarrhea over the entire Treatment Period
[0205] The effectiveness variable ‘resolution of diarrhea over the entire Treatment Period’ will be dichotomized (success vs failure) and the proportion of success between the treatment groups during the treatment period (T0hr-72hr) will be compared. Possible differences between treatment groups will be assessed by a generalized linear mixed model (using SAS® Proc GLIMMIX assuming a binomial distribution and logit link). The model will include the fixed effect of Treatment (IVP or CP), Site and Treatment by Site interaction as random effects with baseline PFS as a covariate.
[0206] Treatment effectiveness will be concluded if there is a significant difference in the success rates between the two treatment groups and percent success is higher in the IVP group compared with the CP group.
Comparison of Diarrhea VCOG-CTCAE yl.l Grade at Screening and at Final Evaluation
[0207] The change in Grade between Screening and the Final Evaluation will be compared between the dogs that received IVP and the dogs that were given CP using analysis of covariance (ANCOVA) modeling with treatment as a fixed effect, and site and treatment by site interaction as random effects with baseline PFS as a covariate.
Time to Last Unformed Stool
[0208] Time to last unformed stool (TLUS) will be presented using Kaplan-Meier methods and compared using a log-rank test. Dogs without a formed stool (score of 6 or 7) will be censored at the time of the last unformed stool. For dogs with only formed stool (scores of 1, 2, 3, 4 or 5) or no stool, the time of occurrence for TLUS will be set to zero.
Frequency of Diarrhea
[0209] ANCOVA modeling with treatment as a fixed effect, and site and treatment by site interaction as random effects with baseline PFS as a covariate will be employed to compare the frequency of diarrhea between IVP and CP.
Example 2: A Study of Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients (Human Subjects)
[0210] Study Design: Chemotherapy induced diarrhea is seen in up to 40-80% of patients receiving this treatment for HER2 positive locally advanced or metastatic breast cancer. This diarrhea can significantly impact a patient's quality of life and ability to tolerate chemo/anti- HER2 therapy. This study will look at the efficacy of the drug crofelemer in preventing diarrhea in breast cancer patients receiving trastuzumab, pertuzumab, and docetaxel or paclitaxel with or without carboplatin (chemotherapeutic regimens referred to as THP and TCHP).
[0211] Protocol:
[0212] Approximately 46 patients will be randomly assigned to the treatment arm or the control. Patients on the treatment arm will take one tablet of crofelemer twice a day (each tablet is 125 mg), to be swallowed whole without chewing or crushing, during cycles 1-2 of chemotherapy with THP or TCHP. Patient will be monitored off crofelemer during cycle 3 of chemotherapy. Patients on the control arm will be on the study for cycles 1-3 of THP or TCHP. Patients on the control arm will not receive crofelemer at any time on this study. A cycle can comprise an infusion of the prescribed THP or TCHP followed by a 21 day duration. See Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med. 2012;366:109-119).
[0213] Eligibility Criteria:
[0214] Patients eligible for the study much be as follows: Willing and able to provide written informed consent; man or woman >18 years of age; pathologically confirmed diagnosis of HER2 positive breast cancer of any stage (previous treatment is allowed without limits on lines of prior therapy); scheduled to receive at least 3 consecutive cycles of THP or TCHP; have a performance status of 0-2 according to the ECOG scale; have a negative pregnancy test at time of informed consent for women of childbearing potential; have a Left Ventricular Ejection Fraction (LVEF) greater or equal to 50% at baseline as determined by either ECHO
or MUGA; and be able to read, understand, follow the study procedure and complete crofelemer, rescue medication, and bowel movement diaries. Patients with brain metastases (including concurrent steroid treatment) are allowed on this study. Patients not eligible for the study include women who are breastfeeding; those with ongoing irritable bowel syndrome (IBS) or colitis (including but not limited to ulcerative colitis, Crohn's disease, microscopic colitis, etc.); those using investigational drugs within 3 weeks of signing consent or foreseen use during the study, chemotherapy, trastuzumab, or pertuzumab within the past 3 weeks, laxatives within the past 7 days, chronic laxatives (> 30 consecutive days), or anti-diarrheal agents (including but not limited to loperamide, octreotide, bismuth, tincture of opium, atropine, probiotics in any form other than food) within the past 7 days, antibiotics within the past 7 days. Patients are also excluded if they have any of the following: any type of ostomy; total colectomy; fecal incontinence; ongoing radiation induced diarrhea or constipation or planned radiotherapy to the abdomen or pelvis while on study; active systemic infection requiring ongoing intervention, including but not limited to oral and intravenous antibiotics, anti-fungals, anti-parasites, anti-virals; major abdominal or pelvic surgery within the past 6 months; inadequate organ function for starting THP or TCHP, which may include the following laboratory results within 28 days prior to signing consent: total bilirubin > upper limit of normal (ULN) (unless the patient has documented Gilbert's syndrome); serum creatinine > 2.0 mg/dL or 177 pmol/L; or AST (SGOT) and ALT (SPGT) > 2.5 ULN.
[0215] Effectiveness Variables:
[0216] Primary outcome measures All-grade diarrhea [Time Frame: 29 months]: Incidence of all grade diarrhea lasting 2 or more consecutive days during cycles 1 and 2 of chemotherapy
[0217] Secondary outcome measures as follows:
[0218] Diarrhea any grade [Time Frame: 29 months] Incidence of diarrhea of any grade, as measured by CTCAE v4.0, by cycle and by stratum
[0219] Grade 3-4 diarrhea [Time Frame: 29 months] Incidence of diarrhea of grade 3-4, as measured by CTCAE v4.0, by cycle and by stratum
[0220] Diarrhea onset [Time Frame: 29 months] Time to onset of first episode of diarrhea of any grade, overall and by stratum
[0221] Diarrhea duration [Time Frame: 29 months] Duration (days) of any grade diarrhea, defined from day 1 to day 21, by cycle in which the episode started and by stratum
[0222] Duration grade 3-4 diarrhea [Time Frame: 29 months] Duration (days) of grade 3- 4 diarrhea, defined from day 1 to day 21, by cycle in which the episode started and by stratum
[0223] Anti-diarrheal medications [Time Frame: 29 months] Use of anti -diarrheal medications (other than study drug), by cycle and grade
[0224] FACIT-D total score [Time Frame: 29 months] Quantitative FACIT-D total score, collected day 1 of each cycle and at the time of study completion, by cycle and by stratum
[0225] FACIT-D diarrhea score [Time Frame: 29 months] Quantitative FACIT-D diarrhea subset (DS) score, by cycle and by stratum
[0226] Stool frequency and consistency [Time Frame: 29 months] Frequency table of stool consistency, as measured by the Bristol Stool scale, by cycle stratum between treatment groups
[0227] All publications, patents, and patent applications cited herein are hereby incorporated herein by reference in their entirety.
Example 3: A Study of the Safety and Effectiveness of Crofelemer for the Treatment of Neratinib-Induced Diarrhea in Beagle Dogs
[0228] Neratinib (Nerlynx®) is an orally available, 6,7-di-substituted-4-anilinoquinoline-3- carbonitrile irreversible inhibitor of the HER-2 receptor tyrosine kinase (also binds EGFR and HER4) with potential antineoplastic activity, and is indicated for the extended adjuvant treatment of adult patients with early stage HER2 -positive (overexpressed/ amplified) breast cancer, to follow adjuvant trastuzumab-based therapy and also for metastatic HER2-positive breast cancer.
[0229] The recommended dose for neratinib is 240 mg, orally once daily. Dose reduction intervals of 40 mg [to a minimum dose of 120 mg once daily] and dose interruptions (cessation of neratinib for up to three weeks) may be utilized, if needed, to manage adverse reactions. Antidiarrheal prophylaxis is initiate using loperamide with the first dose of neratinib and continued during first 2 cycles (56 days) of treatment. This approval was based upon a multicenter, randomized, double-blind, placebo-controlled study (ExteNET).
[0230] It is not expected that any increase in adverse reactions would be noted with the combination of crofelemer and neratinib over neratinib alone, since crofelemer is minimally absorbed and has been demonstrated in human studies to have minimal interaction on pharmacologic exposure of other drugs.
[0231] Severe diarrhea and sequelae, such as dehydration, hypotension, and renal failure, have been reported during treatment with neratinib. Diarrhea was reported in 95% of neratinib-treated patients in ExteNET. Grade 3 diarrhea occurred in 40% and Grade 4 diarrhea occurred in 0.1% of patients. The majority of patients (93%) had diarrhea in the first month of treatment, the median time to first onset of Grade > 3 diarrhea was 8 days (range, 1-350), and the median cumulative duration of Grade > 3 diarrhea was 5 days (range, 1-139).
Objective
[0232] The objective of this study was to evaluate the effects of crofelemer in reducing the incidence and severity of diarrhea following daily oral neratinib dosing for 28 days in healthy female dogs, without the concomitant use of loperamide.
Methods
[0233] Twenty-four healthy adult female beagle dogs with a mean weight of 7.2 kg (range 6.4 - 8.5 kg) were randomized into three groups of 8 dogs each. All dogs received oral neratinib once daily 40 mg/day for the first 5 days; which was escalated to 80 mg/day from day 6 for the remainder of the 28-day period to induce diarrhea as evidenced by the passage of loose/watery stools.
[0234] Group 1 dogs represented the control group that received daily oral neratinib tablets with placebo crofelemer capsules administered orally four times a day (QID) over the 28 day- period. Group 2 received daily oral neratinib tablets with daily crofelemer 125 mg delay ed- release tablet (Mytesi®) and crofelemer capsules administered orally QID over the 28 day- period. Group 3 dogs received daily oral neratinib tablets with daily crofelemer 125 mg delayed-release tablet (Mytesi®) and crofelemer capsules administered orally QID over the 28 day-period.
Table 4. Summary of experimental design
[0235] Dogs were evaluated twice daily for stool consistency and number of bowel movements, which were scored according to a 7-Point Purina Fecal Stool Scale which is analogous to the human Bristol Stool Form Score. Dogs with mild or moderate dehydration were given subcutaneous fluids and/or a single-day neratinib dose reduction or drug holiday to ameliorate their diarrhea severity. No dogs in any treatment group received anti-motility drugs like loperamide at any time to reduce the diarrhea incidence or severity during the 28-day treatment period.
[0236] The pharmacological effects of crofelemer on reducing diarrhea severity following neratinib oral dosing were assessed by: a) Determining the proportion of “responder” dogs defined as dogs with <7 watery stool for at least 2 weeks of the 4-week treatment period; b) Evaluating the average number of watery stools per week in each treatment group; c) Comparing the stool consistency determined by the average fecal scores per week across all treatment groups versus placebo; d) Comparing the average number of watery stools per week per dose of neratinib across all treatment groups and placebo; e) Comparing the average fecal score per week, per dose of neratinib across all treatment groups and placebo; and f) Evaluating the changes in body weight, clinical chemistry, and hematologic parameters across all treatment groups and placebo.
[0237] Summary statistics were computed at each week and pair-wise p-values were computed via t-test to determine differences for the crofelemer-treated groups from the control group. Analysis of covariance (ANCOVA) was conducted using baseline fecal scores as a covariate. Least Squares Mean (LSM) results were adjusted for baseline scores.
Results
[0238] There was no significant difference in body weights, clinical chemistry, and hematologic parameters for any of the treatment groups at any time of the during the 28-day treatment period of this study.
[0239] Three of eight (3/8, 37.5%) control dogs had < 7 watery stools per week for at least
2 of the 4-week period. By contrast, 7 of 8 (87.5%) crofelemer QID-treated dogs and 6 of 8 (75%) crofelemer BID-treated dogs had <7 watery stools per week for 2 of the 4-week treatment period. Logistic regression analysis showed that the control group was significantly different from either crofelemer QID (Odds Raio = 17.8, p-value =0.02) and/or crofelemer BID (Odds Ratio = 26.8, p-value = 0.03). Dogs receiving crofelemer QID were 26.8 times more likely to be “responders” than dogs enrolled in the control group.
Table 5. Examples of responder and non-responder dogs Non-responder: Total watery stools 42
Observe
2x/day
Fecal
Scores
Observe
2x/day
Fecal
Scores
Responder: Total watery stools 29
Observe
2x/day
Fecal
Scores
Observe
2x/day
Fecal
Scores
[0240] The average number of watery stools per week for week 1 and at end of treatment for the entire 4-week treatment period for placebo and crofelemer-treated BID and QID groups are shown in Table 6. The average number of total watery stools over the entire 28-day period were significantly lower for crofelemer BID and QID groups when compared to control dogs (p<0.05).
Table 6. Number of watery stools (WS) per week by treatment group
WS, watery stool; wk, week.
[0241] Stool consistency as measured by the average fecal scores per week demonstrated that crofelemer QID and BID groups had more formed stools while the control group dogs had more loose/watery stools. Results by treatment group are shown in Table 7. There was a trend toward fewer neratinib dose reductions in the crofelemer BID group when compared to the control group (p<0.1). The average number of neratinib dose reduction per week by treatment are shown in Table 8.
Table 7. Average fecal scores (FS) per week by treatment group
Table 8. Number of neratinib dose reductions per week by treatment group
[0242] There was a significant reduction in the average number of watery stools per week per neratinib dose during week 1 as well as over the entire 28-day treatment period for crofelemer BID dogs compared to control. Results for week 1 and overall results are shown in
Table 9
Table. 9 Average number of watery stools (WS) per week per neratinib dose by treatment group
[0243] Stool consistency as measured by the average fecal scores per week per neratinib dose showed significantly more formed stools for crofelemer QID and BID groups over the entire 28-day treatment period compared to control group. The results are shown in Table. 10.
Table 10. Average fecal scores per week per neratinib dose by treatment
Conclusions
[0244] This study demonstrated that crofelemer, a first-class anti-secretory antidiarrheal drug, significantly reduced the incidence and severity of diarrhea associated with daily oral
administration of neratinib, a kinase inhibitor indicated for adjuvant treatment of adult patients with early stage Her-2 positive breast cancer, following trastuzumab-based therapy. This non- clinical study in female dogs was conducted without the concomitant administration of loperamide (an opiate) and demonstrated that crofelemers’ physiological mechanism of action of chloride ion channel regulation results in a significant reduction in diarrhea incidence and severity following neratinib dosing.
[0245] Crofelemer also demonstrated significant improvement in the number of “responders” as defined by a threshold of < 7 watery stools per week for at least 2 weeks of the 4-week treatment period.
Claims (25)
1. A method of treating chemotherapy -induced diarrhea (CID) in a human subject undergoing chemotherapy comprising administering to a subject in need thereof a composition comprising an effective amount of crofelemer to treat CID.
2. The method of claim 1, wherein the crofelemer may be administered in combination with other chemotherapy agents.
3. The method of claim 1, wherein the crofelemer is administered at the same time as chemotherapy to reduce or delay the onset of CID.
4. The method of claim 1, wherein the crofelemer is administered before chemotherapy to prevent, reduce or delay the onset of CID.
5. The method of claim 1, wherein the crofelemer is administered after chemotherapy to reduce the onset of or treat CID.
6. The method of any previous claim, wherein the chemotherapy is selected from alkylating agents, anthracyclines, cytoskeletal disruptors (taxanes), epothilones, histone deacetylase inhibitors, inhibitors of topoisomerase I, inhibitors of topoisomerase II, kinase inhibitors, nucleotide analogs and precursor analogs, peptide antibiotics, platinum-based agents and retinoids.
7. The method of claim 6, wherein the chemotherapy comprises one or more tyrosine kinase inhibitors.
8. The method of claim 7, wherein the tyrosine kinase inhibitor is selected from lapatinib, sunitinib, sorafenib, erlotinib, gefitinib, axitinib, imatinib, nilotinib, dasatinib, cabozantinib, ruxolitinib, neratinib, bosutinib, pazopanib, afatninib, lenvatinib, tucatinib, vandetanib, ceritinib, crizotinib, dacomitinib, and valatinib.
9. The method of claim 7, wherein the tyrosine kinase inhibitor (TKI) is selected from anaplastic lymphoma kinase (ALK) TKI (e.g., crizotinib, ceritinib and alectinib),
10. The method of claim 6, wherein the chemotherapy is a phosphoinositide 3-kinase inhibitor.
11. The method of claim 10, wherein the phosphoinositide 3-kinase inhibitor is alpelisib.
12. The method of claim 6, wherein the chemotherapy is a CDK (cyclin-dependent kinase) 4/6/ inhibitor, optionally, abemaciclib.
13. The method of any one of claims 1 to 6, wherein the chemotherapy comprises one or more HER (Human epidermal growth factor receptor) inhibitors.
14. The method of claim 9, wherein the HER (Human epidermal growth factor receptor) inhibitor is selected from RG7116, RG1273 (pertuzumab, Perjeta®), RG3502 (trastuzumab emantasine, T-DMI), RG597 (trastuzumab, HERCEPTIN), RGA201 (RG7160), erlotinib (Tarceva®), dacomitinib (PF-00299804), PF-05280014 (Pfizer’s biosimilar mAB to RG597).
15. The method of claim 1, wherein the crofelemer is administered after a subject begins to exhibit symptoms of CID.
16. The method of claim 1, wherein the crofelemer is administered for the duration of treatment with the chemotherapy.
17. The method of claim 1, wherein the crofelemer is administered until symptoms of CID are ameliorated and then crofelemer is discontinued.
18. The method of claim 1, wherein the administering comprises administering about 250 mg to about 1000 mg per day; administering about 250 mg per day; administering about 500 mg per day; administering about 1000 mg per day; administering about 125 mg two times per day; administering about 250 mg two times per day; or administering about 500 mg two times per day of crofelemer to a subject in need thereof.
19. The method of claim 1, wherein the crofelemer is administered as an enteric coated oral dosage form.
20. The method of claim 1, wherein the crofelemer is administered as an oral dosage form that is not enteric coated.
21. The method of claim 1, wherein the subject can tolerate a chemotherapeutic agent that the subject could not tolerate without the administration of crofelemer or can tolerate a higher dosage of chemotherapeutic than the subject could tolerate without administration of crofelemer.
22. The method of claim 1, wherein a subject is considered treated if the subject demonstrates one or more of a decrease in the number of bowel movements per day, a decrease in the number of watery bowel movements per day, an improvement in the daily abdominal score for pain or discomfort, an improvement in the score for daily stool consistency, a decrease in stool consistency, a decrease in the number of days per week that subjects experienced urgency, a decrease in the number of days per week that subjects experienced fecal incontinence, or a decrease in the unscheduled visit for a significant worsening of diarrhea.
23. The method of claim 1, wherein the administration results in a decrease in 1, 2 or 3 Grades of the Grade of diarrhea according to the Common Toxicity Criteria.
24. The method of claim 1, wherein the subject is undergoing chemotherapy to treat a cancer selected from breast cancer, ovarian cancer, prostate cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer, kidney cancer, thyroid cancer, oral or oropharyngeal cancer, astrocytoma, sarcoma, mesothelioma, meningioma, lymphoma, myeloma, head and neck cancer, lung cancer, carcinoma (e.g., squamous cell carcinoma), malignant melanoma, peritoneal cancer, gastric cancer, hepatic cancer, colorectal cancer, gallbladder cancer, bone cancer, pancreatic cancer, tongue cancer, esophageal cancer, brain tumor, brain stem glioma, a metastases thereof, and leukemia.
25. A method of treating CID in a human subject undergoing chemotherapy for HER positive breast cancer, said method comprising administering to said human subject a composition comprising an crofelemer at a dose of 125 mg twice per day, wherein the chemotherapy is trastuzumab, pertuzumab, docetaxel, paclitaxel, or neratinib, or a combination thereof, with or without carboplatin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2020/038691 WO2021257089A1 (en) | 2020-06-19 | 2020-06-19 | Methods and compositions for treating chemotherapy-induced diarrhea |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020454132A1 true AU2020454132A1 (en) | 2023-02-02 |
Family
ID=79268234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020454132A Pending AU2020454132A1 (en) | 2020-06-19 | 2020-06-19 | Methods and compositions for treating chemotherapy-induced diarrhea |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4168027A4 (en) |
JP (1) | JP2023538186A (en) |
KR (1) | KR20230027226A (en) |
AU (1) | AU2020454132A1 (en) |
BR (1) | BR112022025741A2 (en) |
CA (1) | CA3182864A1 (en) |
IL (1) | IL299028A (en) |
JO (1) | JOP20220339A1 (en) |
MX (1) | MX2022016367A (en) |
WO (1) | WO2021257089A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115089592B (en) * | 2022-05-21 | 2024-02-27 | 复旦大学 | Application of multiple tyrosine kinase in preparation of medicines for inhibiting enterovirus 71 type neurotropic viruses |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2485596A4 (en) * | 2009-10-06 | 2013-07-17 | Univ California | Methods of treating diseases with proanthocyanidin oligomers such as crofelemer |
MX348184B (en) * | 2010-10-31 | 2017-06-02 | Napo Pharmaceuticals Inc | Methods and compositions for treating hiv-associated diarrhea. |
US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
BR112017014750A2 (en) * | 2015-01-09 | 2018-06-19 | Jaguar Animal Health | methods for treating diarrhea in pets |
EP4295840A3 (en) * | 2016-12-06 | 2024-03-13 | DSM Nutritional Products, LLC | Glycan polymers and related methods thereof |
-
2020
- 2020-06-19 BR BR112022025741A patent/BR112022025741A2/en unknown
- 2020-06-19 WO PCT/US2020/038691 patent/WO2021257089A1/en active Application Filing
- 2020-06-19 MX MX2022016367A patent/MX2022016367A/en unknown
- 2020-06-19 KR KR1020237002209A patent/KR20230027226A/en unknown
- 2020-06-19 JO JOP/2022/0339A patent/JOP20220339A1/en unknown
- 2020-06-19 IL IL299028A patent/IL299028A/en unknown
- 2020-06-19 AU AU2020454132A patent/AU2020454132A1/en active Pending
- 2020-06-19 CA CA3182864A patent/CA3182864A1/en active Pending
- 2020-06-19 EP EP20940856.6A patent/EP4168027A4/en active Pending
- 2020-06-19 JP JP2022578560A patent/JP2023538186A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021257089A1 (en) | 2021-12-23 |
MX2022016367A (en) | 2023-01-30 |
JP2023538186A (en) | 2023-09-07 |
BR112022025741A2 (en) | 2023-01-03 |
CA3182864A1 (en) | 2021-12-23 |
KR20230027226A (en) | 2023-02-27 |
IL299028A (en) | 2023-02-01 |
JOP20220339A1 (en) | 2023-01-30 |
EP4168027A1 (en) | 2023-04-26 |
EP4168027A4 (en) | 2024-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2757373C2 (en) | Combination therapy with antitumor alkaloid | |
Heist et al. | Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer | |
US10973829B2 (en) | Therapeutic uses of a C-RAF inhibitor | |
AU2020222296A1 (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
Ricci et al. | Drug-induced hair colour changes | |
US20220362209A1 (en) | Methods and compositions for treating chemotherapy-induced diarrhea | |
CN108024540A (en) | Method for treating cancer | |
RU2738934C2 (en) | Methods of treating cancer using apilimod | |
CN110494166A (en) | Combination treatment | |
EP3215157B1 (en) | Apilimod for use in the treatment of melanoma | |
JP6860949B2 (en) | How to treat cancer | |
Kouno et al. | Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen | |
Graul et al. | 2012 in review-part I: the year's new drugs & biologics | |
KR20210010524A (en) | Composition comprising a bisfluoroalkyl-1,4-benzodiazepinone compound for the treatment of adenocyst carcinoma | |
AU2020454132A1 (en) | Methods and compositions for treating chemotherapy-induced diarrhea | |
US20200297671A1 (en) | Methods of avoiding excipient-based adverse effects and of exploiting biological properties of gras compounds | |
CN101534840A (en) | Methods for the treatment of radiation proctosigmoitis | |
Choudhary et al. | Different chemosensitization approaches in gastric cancer | |
TW202200127A (en) | Methods and compositions for treating chemotherapy-induced diarrhea | |
BR112021008606A2 (en) | use of tivozanib to treat individuals with refractory cancer | |
RU2729425C2 (en) | Doses of panobinostat for multiple myeloma | |
US20190000791A1 (en) | Isothiocyanatostilbenes as a novel method and product for treating cancer | |
WO2024023766A1 (en) | P13k inhibitor combination therapy | |
KR102356393B1 (en) | Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck | |
Nag | mTOR inhibition in management of advanced breast cancer |